<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="review-article" xml:lang="en" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Curr Opin Virol</journal-id><journal-id journal-id-type="iso-abbrev">Curr Opin Virol</journal-id><journal-id journal-id-type="pmc-domain-id">3815</journal-id><journal-id journal-id-type="pmc-domain">pheelsevier</journal-id><journal-title-group><journal-title>Current Opinion in Virology</journal-title></journal-title-group><issn pub-type="ppub">1879-6257</issn><issn pub-type="epub">1879-6265</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Elsevier - PMC COVID-19 Collection</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC8664555</article-id><article-id pub-id-type="pmcid-ver">PMC8664555.1</article-id><article-id pub-id-type="pmcaid">8664555</article-id><article-id pub-id-type="pmcaiid">8664555</article-id><article-id pub-id-type="pmid">34902803</article-id><article-id pub-id-type="doi">10.1016/j.coviro.2021.11.012</article-id><article-id pub-id-type="pii">S1879-6257(21)00152-8</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Translating known drivers of COVID-19 disease severity to design better SARS-CoV-2 vaccines</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name name-style="western"><surname>Pelletier</surname><given-names initials="AN">Adam N</given-names></name><xref rid="aff0005" ref-type="aff">1</xref></contrib><contrib contrib-type="author" id="aut0010"><name name-style="western"><surname>Sekaly</surname><given-names initials="RP">Rafick P</given-names></name><xref rid="aff0010" ref-type="aff">2</xref><xref rid="aff0015" ref-type="aff">3</xref></contrib><contrib contrib-type="author" id="aut0015"><name name-style="western"><surname>Tomalka</surname><given-names initials="JA">Jeffrey A</given-names></name><xref rid="aff0010" ref-type="aff">2</xref><xref rid="aff0015" ref-type="aff">3</xref></contrib><aff id="aff0005"><label>1</label>RPM Bioinfo Solutions, Blainville, Quebec, Canada</aff><aff id="aff0010"><label>2</label>Pathology Advanced Translational Research Unit, Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA</aff><aff id="aff0015"><label>3</label>Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, USA</aff></contrib-group><pub-date pub-type="ppub"><month>2</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>11</day><month>12</month><year>2021</year></pub-date><volume>52</volume><issue-id pub-id-type="pmc-issue-id">395411</issue-id><fpage>89</fpage><lpage>101</lpage><pub-history><event event-type="pmc-release"><date><day>11</day><month>12</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>14</day><month>12</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-01-16 06:10:13.720"><day>16</day><month>01</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>&#169; 2021 The Author(s)</copyright-statement><copyright-year>2021</copyright-year><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="main.pdf"/><abstract id="abs0010"><p>The SARS-CoV-2 pandemic has highlighted how an emergent disease can spread globally and how vaccines are once again the most important public health policy to combat infectious disease. Despite promising initial protection, the rise of new viral variants calls into question how effective current SARS-CoV-2 vaccines will be moving forward. Improving on vaccine platforms represents an opportunity to stay ahead of SARS-CoV-2 and keep the human population protected. Many researchers focus on modifying delivery platforms or altering the antigen(s) presented to improve the efficacy of the vaccines. Identifying mechanisms of natural immunity that result in the control of infection and prevent poor clinical outcomes provides an alternative approach to the development of efficacious vaccines. Early and current evidence shows that SARS-CoV-2 infection is marked by potent lung inflammation and relatively diminished antiviral signaling which leads to impaired immune recognition and viral clearance, essentially making SARS-CoV-2 &#8216;too hot to handle&#8217;.</p></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><p id="par0030"><bold>Current Opinion in Virology</bold> 2022, <bold>52</bold>:89&#8211;101</p><p id="par0035">This review comes from a themed issue on <bold>Preventive and therapeutic vaccines</bold>
</p><p id="par0040">Edited by <bold>Mehul Suthar</bold> and <bold>Jens Wrammert</bold>
</p><p id="par0045">For complete overview about the section, refer &#8220;<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://https://www.sciencedirect.com/journal/current-opinion-in-virology/special-issue/1051V071C04" id="intr0005">Preventive and therapeutic vaccines (2021)</ext-link>&#8221;</p><p id="par0050">Available online 11th December 2021</p><p id="par0055">
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.coviro.2021.11.012" id="intr0010"><bold>https://doi.org/10.1016/j.coviro.2021.11.012</bold></ext-link>
</p><p id="par0060">1879-6257/&#169; 2021 The Author(s). Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc-nd/4.0/" id="intr0015">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link>).</p><p id="par0065">;1;</p><sec id="sec0005"><title>Inflammation: good or bad for infections and vaccines?</title><p id="par0070">The SARS-CoV-2 pandemic has resulted in an estimated 248 million cases worldwide with over 5 million deaths [<xref rid="bib0005" ref-type="bibr">1</xref>]. Though healthy adults and children generally clear infection with mild to no symptoms, they are able to spread the virus to more vulnerable populations (elderly, obese, diabetic, immunocompromised, etc.) who are more susceptible to developing severe COVID-19 disease. A wealth of literature has been published on SARS-CoV-2 infection and one common theme observed is that severe COVID-19 is a disease characterized by production of potent inflammatory mediators including IL-1b and IL-6, both in the lungs and systemically [<xref rid="bib0010" ref-type="bibr">2</xref>,<xref rid="bib0015" ref-type="bibr">3</xref>,<xref rid="bib0020" ref-type="bibr">4<sup>&#8226;&#8226;</sup></xref>,<xref rid="bib0025" ref-type="bibr">5</xref>,<xref rid="bib0030" ref-type="bibr">6</xref>]. While inflammation is a necessary component of protective immune responses to viral infection, too much inflammation and/or the wrong type of inflammation can lead to poor outcomes. Likewise in vaccination, inflammation is observed to be part of the signature of a good vaccine response [<xref rid="bib0035" ref-type="bibr">7</xref>, <xref rid="bib0040" ref-type="bibr">8</xref>, <xref rid="bib0045" ref-type="bibr">9</xref>, <xref rid="bib0050" ref-type="bibr">10</xref>]. However there are multiple types of inflammation (Interferon-driven, NF-&#954;B driven, MAPK driven, Type 1 versus Type 2) and which types of inflammation are good versus bad at promoting protective immune responses is highly dependent on the nature of the pathogen. So how do we go about investigating what is good inflammation in SARS-CoV-2 vaccination and leveraging this to develop better vaccines? One approach is to leverage Systems Immunology to identify the immune signatures during vaccination which are associated with vaccine efficacy. Arunachalam <italic toggle="yes">et al.</italic> used this approach to identify the components of the immune response which modulate efficacy of the Pfizer-BioNTech BNT162b2 mRNA vaccine. They showed that boosting of this vaccine resulted in significant increases in polyfunctional CD4 and CD8 T cell responses, as well as a potent induction of interferon and inflammatory signaling in monocytes. Interestingly, this inflammation was only present after the boost and did not persist a week after boosting. Could the lack of sustained inflammation account for the waning immunity observed post-vaccination? How can we promote and sustain a proper inflammatory response to SARS-CoV-2 vaccination? Only detailed studies of the approved SARS-CoV-2 vaccines can answer these questions but such studies and data are not currently available.</p></sec><sec id="sec0010"><title>Approved SARS-CoV-2 vaccine platforms</title><p id="par0075">Six COVID-19 vaccines have been approved by the WHO which span four different platforms and have efficacies ranging from 50 to 95%. The four platforms are: 1) the Moderna and Pfizer mRNA vaccines [<xref rid="bib0055" ref-type="bibr">11</xref>,<xref rid="bib0060" ref-type="bibr">12</xref>]; 2) the Johnson &amp; Johnson human Adenovirus (AD26.COV 2.S) [<xref rid="bib0065" ref-type="bibr">13</xref>]; 3) the AstraZeneca AZD1222 chimpanzee Adenovirus (ChAdOx1 vector) vaccine [<xref rid="bib0070" ref-type="bibr">14</xref>]; and 4) the Sinopharm and Sinovac-CoronaVac inactivated virus vaccines [<xref rid="bib0075" ref-type="bibr">15</xref>,<xref rid="bib0080" ref-type="bibr">16</xref>]. The first three platforms encode for the full-length prefusion stabilized spike protein. That efficacy varies among the platforms even though the antigen is similar, with the mRNA platforms having the highest efficacy, supporting the idea that there are specific immune pathways induced by vaccination which promote protection and vary by platform.</p><p id="par0080">The development of more broadly efficacious vaccines is critical for continuing efforts to fight the SARS-CoV-2 pandemic. The emergence of variants including the delta (B.1.617.2) and omicron (B.1.1.529) variants have already begun to raise questions about the efficacy rates of current COVID-19 vaccines [<xref rid="bib0085" ref-type="bibr">17<sup>&#8226;&#8226;</sup></xref>,<xref rid="bib0090" ref-type="bibr">18</xref>,<xref rid="bib0095" ref-type="bibr">19</xref>,<xref rid="bib0100" ref-type="bibr">20<sup>&#8226;&#8226;</sup></xref>]. It has been shown that the neutralizing activity of vaccine-induced antibodies is reduced against variants including the delta, beta (B.1.351), gamma (P.1), kappa (B.1.617.1) and mu (B.1.621) variants [<xref rid="bib0105" ref-type="bibr">21</xref>, <xref rid="bib0110" ref-type="bibr">22</xref>, <xref rid="bib0115" ref-type="bibr">23</xref>, <xref rid="bib0120" ref-type="bibr">24</xref>, <xref rid="bib0125" ref-type="bibr">25</xref>]. Compounding this scenario is the fact that herd immunity has not been, and may never be, reached by a combination of vaccination and natural infection due to a multitude of factors including limitations on vaccine availability around the globe, the fact that high vaccine efficacy rates are benchmarked against preventing severe disease not infection/transmission, vaccine hesitations/concerns and preexisting medical conditions. Herd immunity is a population state in which a large enough percentage of individuals are immune to infection such that it nearly abrogates disease transmission between individuals thus providing protection of the whole population to the spread of disease. Common examples of vaccine-induced herd immunity are measles, mumps, and smallpox for which infections do still occur but they are not able to spread. Higher rates of infection and transmission associated with SARS-CoV-2 variants further limits the potential for herd immunity. As a result, SARS-CoV-2 viruses continue to circulate, inevitably giving rise to new variants which will further impact the efficacy of approved vaccines. This may lead to a seasonal infection similar to Influenza and the other endemic &#946;-Coronaviruses. So where do we go from here to develop a better vaccine?</p></sec><sec id="sec0015"><title>Adjuvants as a means to the end of better vaccine efficacy</title><p id="par0085">Altering the antigenic component of a vaccine is not the only way to improve the efficacy of the response. The components of the vaccine platform themselves, including delivery methods, formulation, and adjuvant, can directly impact how the immune system responds to the vaccination and modulate whether or not protective responses are induced. Recent results from Arunachalam <italic toggle="yes">et al.</italic> showed that modifying the adjuvant included with a RBD protein subunit can modulate immune responses including Ab magnitude and breadth of variant neutralization, T cell responses and protection from viral challenge supporting the idea that inclusion of adjuvants which drive the proper protective immune responses is critical for enhancing efficacy [<xref rid="bib0130" ref-type="bibr">26<sup>&#8226;&#8226;</sup></xref>]. Similar differences in vaccine efficacy based on adjuvant inclusion were shown, specifically, for Alum and MF59 in the context of SIV/HIV [<xref rid="bib0135" ref-type="bibr">27</xref>,<xref rid="bib0140" ref-type="bibr">28<sup>&#8226;</sup></xref>] as well as TB and Influenza [<xref rid="bib0145" ref-type="bibr">29</xref>]. This work, done by our group and others, demonstrates that Alum and MF59 induce distinct inflammatory immune profiles during vaccination which directly modulates the efficacy of vaccine responses; whether this modulation promotes or reduces vaccine efficacy is platform and pathogen dependent. That distinct adjuvants induced a different magnitude and quality of the SARS-CoV-2 (and others) vaccine response isn&#8217;t surprising, yet the expedited nature of SARS-CoV-2 vaccine development meant no testing was performed to study the impact of adjuvants. Understanding the inflammatory pathways which drive protective COVID-19 vaccine responses and how these pathways are differentially modulated by available vaccine platforms and adjuvants is critical to the development of next generation COVID-19 vaccines. Unfortunately, the data does not currently exist to comprehensively compare the protective immune responses across the currently approved COVID-19 vaccine platforms. In the absence of such data, how can we begin to understand the key inflammatory cells and pathways important for vaccine responses to SARS-CoV-2?</p><p id="par0090">Informative and relevant knowledge could be garnered from studies of an efficient natural immune response triggered upon SARS-CoV-2 infection and which would lead to the protection from dissemination of infection and from the development of poor clinical outcomes in infected subjects. Understanding the dysregulation of natural immunity during infection will provide insights into immune pathways which contribute to pathology and thus might not be effective at preventing infection. At the same time, immune pathways which are suppressed in severe cases compared to mild or asymptomatic cases could represent key targets to boost the immune response and improve vaccine efficacy. We will now discuss a critical immune mechanism associated with severe disease that can help inform on developing more efficacious vaccines.</p></sec><sec id="sec0020"><title>Inflammation is a hallmark of COVID-19 disease progression</title><p id="par0095">COVID-19 is characterized by progressive inflammation, lung damage, and lymphopenia which culminate in severe respiratory distress and cytokine storm in patients with severe COVID-19 disease [<xref rid="bib0010" ref-type="bibr">2</xref>,<xref rid="bib0015" ref-type="bibr">3</xref>,<xref rid="bib0020" ref-type="bibr">4<sup>&#8226;&#8226;</sup></xref>,<xref rid="bib0025" ref-type="bibr">5</xref>,<xref rid="bib0030" ref-type="bibr">6</xref>]. It has become evident that the SARS-CoV-2 virus utilizes multiple subversions of the human immune system including driving inflammation and the inhibition of the antiviral innate interferon responses [<xref rid="bib0150" ref-type="bibr">30</xref>,<xref rid="bib0155" ref-type="bibr">31</xref>]; this promotes viral persistence, mainly in individuals with pre-existing co-morbidities (age, high BMI, diabetes, etc.) or who are immunocompromised, by driving an aberrant immune response that is not capable of controlling the SARS-CoV-2 virus within the first 1&#8211;2 weeks of infection, as is normally the case for most infected individuals. Dampened interferon (IFN) responses during acute infection <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> distinguish SARS-CoV-2 from other respiratory infections including Respiratory Syncytial virus (RSV) and Influenza A virus (IAV) [<xref rid="bib0160" ref-type="bibr">32<sup>&#8226;&#8226;</sup></xref>,<xref rid="bib0165" ref-type="bibr">33</xref>]. Select human clinical trials using IFN treatment have shown efficacy in reducing disease severity, disease longevity, recovery from symptoms and mortality, indicating that interferons may be critical for limiting COVID-19 disease [<xref rid="bib0170" ref-type="bibr">34</xref>, <xref rid="bib0175" ref-type="bibr">35</xref>, <xref rid="bib0180" ref-type="bibr">36</xref>]. This early IFN signaling is responsible for priming cells towards an anti-viral state that allows the control of viral dissemination. In the absence of a potent induction of antiviral interferons stimulated genes (ISGs), SARS-CoV-2 virus can persist in the upper and lower airway epithelium leading to infectious spread to the circulation and progressive COVID-19 disease. It is known that inflammasomes and IFNs regulate each other; inflammasomes antagonize IFN responses by cleaving cGAS to limit IFN production downstream of cGAS/STING; IFN signaling has been shown to suppress inflammasome activation in response to multiple stimuli including the adjuvant Alum [<xref rid="bib0185" ref-type="bibr">37</xref>, <xref rid="bib0190" ref-type="bibr">38</xref>, <xref rid="bib0195" ref-type="bibr">39</xref>]. Thus, scales tipped too far in favor of inflammation over IFN signaling could be a major contributing factor to the severity of acute infection, the subsequent down regulation of effective innate and adaptive immune responses, and disease progression. So then, what is the source of this deleterious inflammation?</p><p id="par0100">Progression to severe COVID-19 is highlighted by a local and systemic inflammatory response and the subsequent degeneration of respiratory function. Evidence from SARS-CoV-2 infected patients highlight inflammasomes and IL-1&#946; as potential critical mediators of this inflammation [<xref rid="bib0025" ref-type="bibr">5</xref>]. Inflammasomes are cytosolic, multi-protein complexes which mediate activation of inflammatory caspases and the eventual processing of pro-IL-1&#946; and pro-IL-18 into their biologically active forms. Inflammasomes can be activated in response to a wide range of stimuli, including bacteria [<xref rid="bib0200" ref-type="bibr">40</xref>, <xref rid="bib0205" ref-type="bibr">41</xref>, <xref rid="bib0210" ref-type="bibr">42</xref>, <xref rid="bib0215" ref-type="bibr">43</xref>, <xref rid="bib0220" ref-type="bibr">44</xref>], fungi [<xref rid="bib0225" ref-type="bibr">45</xref>, <xref rid="bib0230" ref-type="bibr">46</xref>, <xref rid="bib0235" ref-type="bibr">47</xref>] and host DAMPs [<xref rid="bib0240" ref-type="bibr">48</xref>,<xref rid="bib0245" ref-type="bibr">49</xref>] as well as, to a lesser extent, viruses [<xref rid="bib0250" ref-type="bibr">50</xref>, <xref rid="bib0255" ref-type="bibr">51</xref>, <xref rid="bib0260" ref-type="bibr">52</xref>]. These cytokines are potent inflammatory regulators which drive leukocyte chemotaxis, activation, and differentiation. IL-1&#946; in tissue activates potent neutrophil and macrophage responses to combat extracellular infection and cellular dysfunction caused by tissue damage [<xref rid="bib0230" ref-type="bibr">46</xref>,<xref rid="bib0265" ref-type="bibr">53</xref>, <xref rid="bib0270" ref-type="bibr">54</xref>, <xref rid="bib0275" ref-type="bibr">55</xref>, <xref rid="bib0280" ref-type="bibr">56</xref>]. In line with this, altered neutrophil and macrophage responses are hallmarks of COVID-19 lung damage and disease progression [<xref rid="bib0285" ref-type="bibr">57</xref>,<xref rid="bib0290" ref-type="bibr">58</xref>,<xref rid="bib0295" ref-type="bibr">59<sup>&#8226;&#8226;</sup></xref>,<xref rid="bib0300" ref-type="bibr">60</xref>, <xref rid="bib0305" ref-type="bibr">61</xref>, <xref rid="bib0310" ref-type="bibr">62</xref>]. Evidence of inflammasome activation is also present in the blood of patients with severe COVID-19 [<xref rid="bib0315" ref-type="bibr">63<sup>&#8226;</sup></xref>,<xref rid="bib0320" ref-type="bibr">64</xref>].</p><p id="par0105">Inflammasome activation also routinely induces a lytic form of cell death called pyroptosis which is mediated by cleavage of Gasdermins, canonically Gasdermin-D, and their insertion as multimeric pores into cellular membranes [<xref rid="bib0325" ref-type="bibr">65</xref>,<xref rid="bib0330" ref-type="bibr">66</xref>]. The resulting perturbation in ion homeostasis (K+ efflux and Ca2+ influx/mobilization) leads to cellular rupture and release of inflammatory components normally sequestered within the cytosol of the cell. One of these components, Lactate Dehydrogenase or LDH, is a marker for COVID-19 disease severity and progression supporting that inflammasome induced cell death is a driver of COVID-19 pathology [<xref rid="bib0335" ref-type="bibr">67</xref>,<xref rid="bib0340" ref-type="bibr">68<sup>&#8226;</sup></xref>,<xref rid="bib0345" ref-type="bibr">69</xref>]. Heightened cell death induced by inflammasomes combined with the capacity of IL-1&#946; to promote chemokine production and extravasation of cells into tissues could explain the acute and persistent lymphopenia observed in COVID-19 patients [<xref rid="bib0350" ref-type="bibr">70</xref>, <xref rid="bib0355" ref-type="bibr">71</xref>, <xref rid="bib0360" ref-type="bibr">72</xref>]. Systemically, IL-1&#946; mediates its effects through direct binding to the cell as well as through inducing production of secondary inflammatory mediators including IL-6 and CRP [<xref rid="bib0365" ref-type="bibr">73</xref>, <xref rid="bib0370" ref-type="bibr">74</xref>, <xref rid="bib0375" ref-type="bibr">75</xref>], both of which have been identified as critical determinants of disease progression and severity [<xref rid="bib0370" ref-type="bibr">74</xref>,<xref rid="bib0380" ref-type="bibr">76</xref>, <xref rid="bib0385" ref-type="bibr">77</xref>, <xref rid="bib0390" ref-type="bibr">78</xref>, <xref rid="bib0395" ref-type="bibr">79</xref>]. With this mounting evidence for inflammasome signaling being a central player in COVID-19 disease progression, the next step would be to identify potential cellular sources of SARS-CoV-2-dependent inflammasome activation.</p></sec><sec id="sec0025"><title>Lung inflammation spreads from epithelial cells to infiltrating cells</title><p id="par0110">Given that the upper airway and lungs are the primary target of SARS-CoV-2 infection, it is logical to hypothesize that cells resident to and/or infiltrating into the lungs would be the initial source of this inflammasome activation. <italic toggle="yes">In vitro</italic> infection of human monocytes with SARS-CoV-2 induced inflammasome activation and cell death [<xref rid="bib0315" ref-type="bibr">63<sup>&#8226;</sup></xref>,<xref rid="bib0400" ref-type="bibr">80</xref>]. Yet, airway epithelial cells are the main targets of natural SARS-CoV-2 infection, not monocytes.</p><p id="par0115">To understand how IL-1 and inflammasome signaling is activated and spreads among the first line of immune defense, we probed publicly available datasets of single cell RNA sequencing of bronchioalveolar lavage fluid (BALF) [<xref rid="bib0405" ref-type="bibr">81<sup>&#8226;&#8226;</sup></xref>]. Liao <italic toggle="yes">et al.</italic> found that in severe COVID-19 disease there is heightened infiltration of macrophages and neutrophils into the BALF. To confirm these findings, we mined transcriptional profiles from the Human Cell Atlas and Human Protein Atlas to encapsulate a wider set of cells and visualize clusters using UMAP. Visual comparison of cluster frequency between healthy, mild, and severe disease shows accumulation of epithelial cells, neutrophils, and a shift in the monocyte population (<xref rid="fig0005" ref-type="fig">Figure 1</xref>
a). Quantitative assessment of frequencies of cell clusters shows significant increase in the frequency of epithelial cells within BALF from patients with severe disease compared to healthy controls and mild disease (<xref rid="fig0005" ref-type="fig">Figure 1</xref>b). Gene Set Enrichment Analysis (GSEA) was performed to identify if IL-1 and inflammasome related pathways were being differentially modulated in the epithelial cells from severe COVID-19 as compared to mild COVID-19 and healthy controls. Indeed, we observed heightened expression of key pathways of IL-1 signaling and NF-&#954;B inflammation in epithelial cells from severe COVID-19 compared to mild disease or healthy controls (<xref rid="fig0005" ref-type="fig">Figure 1</xref>c). Multiple key inflammatory mediators (including IL-18, CXCL1, CCL2<bold>)</bold> and transcriptional regulators (including KLF4, FOS, JUN, MYC, NFKB2, NFKBIE) were among the leading-edge genes from the Hallmark NF-&#954;B pathway (<xref rid="fig0005" ref-type="fig">Figure 1</xref>d). Interestingly, expression of genes in the INFLAMMASOME pathway, including CASP1 which encodes for Caspase-1, are reduced in severe disease. The simultaneous heightened IL-1/inflammatory signaling and diminished inflammasome expression in epithelial cells, normally upregulated by inflammatory signaling, suggests that epithelial cells in severe disease which express inflammasomes die; the resulting inflammatory signaling then spreads to the remaining neighboring epithelial cells.<fig id="fig0005" position="float" orientation="portrait"><label>Figure 1</label><caption><p>Epithelial cells in the BALF of severe COVID-19 patients are elevated in frequency and have heightened inflammatory signaling.</p><p>Single cell sequencing of the BALF from three healthy controls and three mild and six severe COVID-19 patients was analyzed. Cells were clustered using UMAP and cell identify annotated using the Human Cell Atlas and Human Protein Atlas. <bold>(a)</bold> UMAP visualization of cells/clusters split into healthy control, mild and severe COVID-19. <bold>(b)</bold> The frequency of epithelial cells in the BALF is significantly enhanced in severe disease compared to healthy controls, with a similar trend seen in mild versus healthy controls. <bold>(c)</bold> Gene Set Enrichment Analysis (GSEA) was performed to identify how pathways of inflammation and IL-1 signaling compared between severe disease and mild disease or healthy controls. Inflammatory signaling including by NF-kB is significantly increased in severe disease. <bold>(d)</bold> Heatmap of expression of the leading edge genes from NF-kB signaling which are enhanced in severe disease. Comparison of cluster frequencies was performed using paired-Wilcoxon sum rank test.</p></caption><alt-text id="at0080">Figure 1</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr1_lrg.jpg"/></fig></p><p id="par0120">Analysis of infiltrating leukocyte populations revealed that there were significantly elevated neutrophils in severe disease compared to mild or healthy controls (<xref rid="fig0010" ref-type="fig">Figure 2</xref>
a). Increased monocyte derived macrophages and decreased alveolar macrophages are a feature of both mild and severe disease, with severe disease showing more significant modulations (<xref rid="fig0010" ref-type="fig">Figure 2</xref>b). Pathway analysis for inflammatory and IL-1 pathways reveals that inflammatory pathways are significantly elevated in severe versus mild disease for all subsets of monocytes/macrophages probed and neutrophils. Thus, not only are there more neutrophils and monocyte derived macrophages in severe disease but these cells are also in a heightened inflammatory status. IL-1 signaling pathway genes upregulated in neutrophils during severe disease include IL-1B itself, suggesting a potential additional source of IL-1&#946; <italic toggle="yes">in vivo</italic>, early targets (IL1RN, HMGB1) and regulators of IL-1/NF-kB signaling (IL1R1, IRAK1/3, RELA, NFKB1/2, NFKBIA). In this way, severe COVID-19 disease is marked by the infiltration of circulating neutrophils and monocytes, which become macrophages, that sense the inflammation driven by IL-1 signaling in epithelial cells and become primed for inflammatory responses. These potently activated neutrophils and macrophages can then mediate tissue damage through the production of proteases (MMPs, Elastase, etc.) which degrade extracellular components, cytokine production and cell death. Cell death releases inflammatory mediators which further exacerbate cell activation and tissue damage. Inflammation generated in the lungs can then spread to the periphery, as evidenced by previous discussion of systemic markers of inflammasome and inflammation, where a cytokine storm drives progressive dysfunction and disease severity. Inflammasome activation that is localized to the lungs and limited in the circulating blood could explain why the cytokine storm in COVID-19 does not lead to the rapid and high mortality traditionally associated with microbial sepsis. Microbial sepsis [<xref rid="bib0410" ref-type="bibr">82</xref>] is a disease where inflammasome activation and inflammation within the blood drives rapid multi-system organ failure and death in contrast to the prolonged disease course associated with the cytokine storm seen in severe COVID-19. <xref rid="fig0015" ref-type="fig">Figure 3</xref>
provides a model of initial inflammatory signaling that is activated in the lungs in response to SARS-CoV-2, and potentially mucosal microbial dysbiosis, and spreads to the periphery, driving disease severity and eventually mortality. Thus, vaccines which include adjuvants, or vectors, that augment or exacerbate tissue inflammation as is seen in SARS-CoV-2 infection may not produce robust or effective immune responses following vaccination.<fig id="fig0010" position="float" orientation="portrait"><label>Figure 2</label><caption><p>Infiltrating neutrophils and monocytes into the lung acquire an inflammatory phenotype and dominate the local immune response to SARS-CoV-2.</p><p>Using the same data as in <xref rid="fig0005" ref-type="fig">Figure 1</xref>, we analyzed the frequency and gene expression status of immune cells in the BALF. <bold>(a)</bold> Neutrophil frequencies were significantly increases in the BALF of severe disease versus mild disease and healthy controls. Monocyte-derived macrophages were also significantly increased in severe disease versus healthy controls, with an increase also observed in mild disease. <bold>(b)</bold> We observe a concomitant loss of resident alveolar macrophages in severe and mild disease. These data suggest that infiltrating neutrophils/monocytes begin to dominate the local lung immune response during severe COVID-19. <bold>(c)</bold> GSEA analysis per cell cluster reveals a consistent signature of upregulated inflammation in immune subsets including in monocytes/macrophages, alveolar macrophages and neutrophils. <bold>(d)</bold> Leading edge genes from the IL-1 signaling pathway reveal key regulators of IL-1&#946;/NF-&#954;B are upregulated in infiltrating immune cells in severe COVID-19 disease. Comparison of cluster frequencies was performed using paired-Wilcoxon sum rank test.</p></caption><alt-text id="at0085">Figure 2</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr2_lrg.jpg"/></fig><fig id="fig0015" position="float" orientation="portrait"><label>Figure 3</label><caption><p>Model of the induction and spread of inflammasome/IL-1&#946; driven inflammation from the lung to the periphery in COVID-19.</p><p>In <bold>Step i</bold>, SARS-CoV-2 virus infected epithelial cells and leads to intrinsic inflammasome activation and inflammatory signaling from infected epithelial cells in <bold>Step ii</bold>. This local inflammatory response promotes chemokine production and leads to the infiltration of circulating leukocytes including innate and adaptive immune cells to the lungs in <bold>Step iii</bold>. The rampant inflammatory response activates these infiltrating cells eventually leading to <bold>Step iv</bold> involving degranulation and/or cell death of immune cells further exacerbating inflammation; this process culminates in further damage to the lung tissue including epithelial cells in <bold>Step v</bold>. This inflammatory response does not remain local and spreads to the periphery causing (<bold>Step vi</bold>) cytokine storm and eventually the need for oxygen, mechanical ventilation and death in severe cases.</p></caption><alt-text id="at0090">Figure 3</alt-text><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="gr3_lrg.jpg"/></fig></p></sec><sec id="sec0030"><title>Implications for vaccine development</title><sec id="sec0035"><title>Avoiding the bad inflammation</title><p id="par0125">So what does this mean for the development of the next generation of COVID-19 vaccines? If inflammasome and IL-1 activation do not induce protective immunity to natural infection, we may consider avoiding using vaccine components which can potently activate the inflammasomes. Though inflammasome/IL-1 activation is often thought of only as a modulator of innate immunity, it also modulates adaptive immune function. It has been shown that inflammasome activation in vaccines can enhance CD4 polyfunctionality, T follicular helper responses and the magnitude of Ab titers [<xref rid="bib0415" ref-type="bibr">83</xref>,<xref rid="bib0420" ref-type="bibr">84</xref>]. In yellow fever virus (YFV), vaccination with YFV17D is associated with inflammasome activation which, combined with complement and interferons, leads to a broad and polyfunctional T cell and B cell response post-vaccination [<xref rid="bib0425" ref-type="bibr">85</xref>]. IL-1 and IL-18 are associated with T helper subset skewing of Th1 and Th17 responses [<xref rid="bib0415" ref-type="bibr">83</xref>,<xref rid="bib0430" ref-type="bibr">86</xref>, <xref rid="bib0435" ref-type="bibr">87</xref>, <xref rid="bib0440" ref-type="bibr">88</xref>]. IL-18 produced by DCs has also been shown to induce antigen-independent production of IFN-gamma from effector CD8+ T cells [<xref rid="bib0445" ref-type="bibr">89</xref>].</p><p id="par0130">The licensed adjuvant Alum [<xref rid="bib0450" ref-type="bibr">90</xref>,<xref rid="bib0455" ref-type="bibr">91</xref>] is known to activate the NLRP3 inflammasome. Likewise, certain DNA viral vectors including Adenoviruses [<xref rid="bib0460" ref-type="bibr">92</xref>,<xref rid="bib0465" ref-type="bibr">93</xref>] and modified vaccinia virus Ankara (19543380) lead to activation of inflammasomes including AIM2 [<xref rid="bib0470" ref-type="bibr">94</xref>], IFI16 and NLRP3. The widespread use of Alum as an adjuvant suggests that inflammasome activation is important for vaccine responses, however there is controversy concerning this subject. There are multiple publications which have published data showing that the NLRP3 inflammasome is dispensable for the adjuvant effect of Alum [<xref rid="bib0475" ref-type="bibr">95</xref>, <xref rid="bib0480" ref-type="bibr">96</xref>, <xref rid="bib0485" ref-type="bibr">97</xref>]. Similarly, while flagellin has been shown to be an adjuvant [<xref rid="bib0490" ref-type="bibr">98</xref>,<xref rid="bib0495" ref-type="bibr">99</xref>], it has been shown that the adjuvant activity of flagellin can be independent of NLRC4 [<xref rid="bib0500" ref-type="bibr">100</xref>,<xref rid="bib0505" ref-type="bibr">101</xref>], the inflammasome known to be activated by flagellin [<xref rid="bib0500" ref-type="bibr">100</xref>]. So while Alum is a potent adjuvant, it is far from clear how dependent this effect is on inflammasome activity. Inflammatory caspases are not the only mechanisms of activating IL-1 cytokines. There are multiple sources of proteases including neutrophils which can mediate cleavage and activation of IL-1 (reviewed in Ref. [<xref rid="bib0510" ref-type="bibr">102</xref>]).</p><p id="par0135">Inflammasome activity in the context of other vaccines is also ambiguous. In influenza, it was recently shown that heightened inflammasome activation, resulting from antibiotic treatment, was associated with lower H1N1-specific neutralizing and binding IgG and IgA [<xref rid="bib0515" ref-type="bibr">103</xref>]. However in HIV/SIV, it has been shown that the canarypox vector ALVAC, a known activator of the inflammasome via AIM2 [<xref rid="bib0520" ref-type="bibr">104</xref>], promotes vaccine efficacy by inflammasome activation in monocytes NHP [<xref rid="bib0525" ref-type="bibr">105</xref>]. We have recently published that ALVAC induced CREB1 activation, a critical modulator of reduced HIV-1 acquisition in humans and protection from SIV challenge in NHP, was associated with IL-18 production which regulated pathways of immune activation in DCs [<xref rid="bib0135" ref-type="bibr">27</xref>].</p><p id="par0140">In the context of SARS-CoV-2, the two approved inactivated virus vaccines, Sinopharm and Sinovac-CoronaVac, both use Alum as adjuvant and have reported lower efficacy rates than the mRNA-based vaccines from Moderna and Pfizer. A recent study used Systems Vaccinology to investigate the immune responses induced by the Pfizer vaccine. Of pertinence, they did not observe potent or persistent inflammation post-vaccination, however they did not compare this to any other SARS-CoV-2 vaccine [<xref rid="bib0530" ref-type="bibr">106<sup>&#8226;&#8226;</sup></xref>]. It is prudent and necessary to better understand how inflammasome activation and inflammation during SARS-CoV-2 vaccination modulates vaccine efficacy and long-lived immunity. Controlled clinical studies are needed to compare Alum with other adjuvants (MF59, TLR ligands) to clearly understand the innate immune responses needed during vaccination to promote vaccine efficacy. We can learn lessons from what does and does not work for the immune response during natural infection to continue to inform vaccine development.</p></sec><sec id="sec0040"><title>Augmenting the good inflammation</title><p id="par0145">By identifying dampened Interferon antiviral responses as a hallmark of SARS-CoV-2 infection and disease, we can now envision designing vaccine regimens which potently induce IFN responses to augment the generation of cells which can combat SARS-CoV-2 infection. A recent study of Influenza vaccination identified epigenetic changes which persisted after vaccination in monocytes and DCs which were correlated with protection from subsequent viral challenge, both to homologous (same) and heterologous (different; Zika and Dengue) viruses [<xref rid="bib0535" ref-type="bibr">107<sup>&#8226;&#8226;</sup></xref>]. Another study, which used a Systems Immunology approach to dissect the immune responses generated in human to the Pfizer-BioNtech SARS-CoV-2 vaccine, showed that antiviral and IFN signaling pathways were more potently induced in monocytes and DCs after the boost (2nd dose) compared to the prime (1st dose) [<xref rid="bib0530" ref-type="bibr">106<sup>&#8226;&#8226;</sup></xref>]. Both of these studies indicate the acquisition of Trained Immunity, a newly described process whereby exposure of innate immune cells to pathogenic stimuli induces epigenetic changes which augment future innate immune responses to challenge [<xref rid="bib0540" ref-type="bibr">108</xref>, <xref rid="bib0545" ref-type="bibr">109</xref>, <xref rid="bib0550" ref-type="bibr">110</xref>, <xref rid="bib0555" ref-type="bibr">111</xref>]. This has tremendous implications for vaccine development as these heightened innate immune responses could help limit breakthrough infections in vaccinated individuals. This includes infections with viral variants as innate immune responses are antigen-independent and unlikely to be substantially impacted by mutations observed in viral variants.</p><p id="par0150">Adjuvants are currently in development and pre-clinical/clinical testing which may potently induce interferon signaling including TLR agonists [<xref rid="bib0560" ref-type="bibr">112</xref>, <xref rid="bib0565" ref-type="bibr">113</xref>, <xref rid="bib0570" ref-type="bibr">114</xref>] and small molecule STING agonists [<xref rid="bib0575" ref-type="bibr">115</xref>, <xref rid="bib0580" ref-type="bibr">116</xref>, <xref rid="bib0585" ref-type="bibr">117</xref>]. We know from a recent study that inclusion of 5 distinct adjuvants in a protein subunit COVID-19 vaccine results in differential modulation of vaccine response. Specifically, 4 adjuvants targeting antiviral/interferon signaling showed efficacy while an oil-in-water formulation did not [<xref rid="bib0130" ref-type="bibr">26<sup>&#8226;&#8226;</sup></xref>]. Within the 4 successful adjuvants, there was variance in protection with all adjuvants inducing no detectable virus in the BAL but in the nares, there was no detectable viral RNA in four of five monkeys for AS03 and CpG-Alum compared to only three of five monkeys for AS37 and Alum. Different nucleic acid composition of vaccine vectors may be differentially sensed by TLRs and cytosolic sensors of nucleic acids leading to downstream differences in interferon signaling.</p><p id="par0155">What we learn about the pathogenesis of SARS-CoV-2 infection can inform how the research community approaches profiling and identifying the immune correlates of protection during COVID-19 vaccination, across multiple platforms. A targeted approach to optimize the platform(s) ultimately chosen for future COVID-19 vaccines represents an opportunity to improve on the overall efficacy of vaccines, irrespective of antigen inclusion. While inflammation is a necessary component of vaccine responses, too much vaccine induced inflammation may not yield protective responses in COVID-19 vaccines. Identifying what constitutes good inflammation versus bad inflammation for SARS-CoV-2 vaccination requires controlled studies which access samples within days of vaccination and link these early signatures to long-term protection; a difficult task made even more difficult by the increasingly lower number of individuals na&#239;ve to SARS-CoV-2 infection and/or vaccination. An ideal adjuvant may be one that is capable of potently inducing interferon/antiviral responses while maintaining enough inflammation to drive chemotaxis and jump start the immune response. Identifying potential pathways ahead of time provides the opportunity to stay ahead of SARS-CoV-2 by not waiting potentially years for detailed immune analyses of current vaccine(s) to inform on vaccine design. Using available data on natural SARS-CoV-2 infection and COVID-19 disease allows us to be more proactive in designing the future of COVID-19 vaccines.</p></sec></sec><sec id="sec0045"><title>Methods</title><sec id="sec0050"><title>Single-cell transcriptomics</title><p id="par0160">Raw count matrices for BALF single-cell RNA-seq data were extracted from SRA Archive <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-geo" xlink:href="GSE145926">GSE145926</ext-link> and imported into the R package Seurat for preprocessing.</p><p id="par0165">Cells with high mitochondrial content (&gt;0.1 of reads) and low number of reads (&lt;200) were filtered out for Quality Control. Expression was integrated across patients using the SCTransform approach from Seurat using 3000 genes as anchors on the basis of their high variance across cells, while an additional 4000 genes were also integrated using those same anchors. Principal component was performed on normalized integrated data, and the optimal number of components was inferred (25) using the Elbow method for clustering and UMAP dimension reduction.</p><p id="par0170">SingleR was used to infer cell identity of individual clusters on the basis of the expression of their top 100 most differentially expressed genes (FindAllMarkers function, Seurat) in comparison with the Human Cell Atlas (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.humancellatlas.org/" id="intr0020">https://www.humancellatlas.org/</ext-link>) and Monaco reference profiles from the Human Protein Atlas (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.proteinatlas.org/" id="intr0025">https://www.proteinatlas.org/</ext-link>). Clustered inferred with the same cell type were merged together to facilitate downstream analysis.</p><p id="par0175">MAST was used to perform differential expression across severity groups, or versus viral counts/cell frequencies, by using raw counts and taking into account cellular detection rate and sample provenance as covariates.</p><p id="par0180">Gene Set Enrichment Analysis (GSEA) was performed using the z score from the MAST analysis as ranking variable, and was tested against inflammasome/apoptosis genesets.</p><p id="par0185">Median expression per gene/cell type/sample was computed and used for visualization purposes in heatmap format. The combined leading edge genes across contrasts was extracted on significant GSEA enrichments, and was leveraged to generate row-normalized heatmaps of pathways across cells and patients.</p></sec></sec><sec id="sec0055"><title>Authors&#8217; contribution</title><p id="par0190">ANP performed bioinformatic analysis, interpretation of results and edited the manuscript. RPS aided in interpretation of results and preparation/editing of manuscript. JAT devised the conceptual basis of the manuscript, planned bioinformatic analysis, interpreted results and drafted the manuscript.</p></sec><sec id="sec0060"><title>Funding</title><p id="par0195">This research was supported by <funding-source id="gs0005">NCI/NHI</funding-source>
U54CA260563 and <funding-source id="gs0010">NIAID/NIH</funding-source>
U19AI128910.</p></sec><sec id="sec0065"><title>Conflict of interest statement</title><p id="par0200">Nothing declared.</p></sec><sec id="sec0070"><title>References and recommended reading</title><p id="par0205">Papers of particular interest, published within the period of review, have been highlighted as:<list list-type="simple" id="lis0010"><list-item id="lsti0030"><p id="par0210">&#8226; of special interest</p></list-item><list-item id="lsti0035"><p id="par0215">&#8226;&#8226; of outstanding interest</p></list-item></list>
</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><mixed-citation publication-type="other" id="oref0005"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://ourworldindata.org/coronavirus-data" id="intr0035">https://ourworldindata.org/coronavirus-data</ext-link>.</mixed-citation></ref><ref id="bib0010"><label>2</label><element-citation publication-type="journal" id="sbref0010"><person-group person-group-type="author"><name name-style="western"><surname>Conti</surname><given-names>P.</given-names></name><name name-style="western"><surname>Ronconi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Caraffa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gallenga</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Ross</surname><given-names>R.</given-names></name><name name-style="western"><surname>Frydas</surname><given-names>I.</given-names></name><name name-style="western"><surname>Kritas</surname><given-names>S.K.</given-names></name></person-group><article-title>Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by Coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies</article-title><source>J Biol Regul Homeost Agents</source><volume>34</volume><year>2020</year><fpage>327</fpage><lpage>331</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.23812/CONTI-E</pub-id><pub-id pub-id-type="pmid">32171193</pub-id></element-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ling</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>B.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Viral and host factors related to the clinical outcome of COVID-19</article-title><source>Nature</source><volume>583</volume><year>2020</year><fpage>437</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">32434211</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-020-2355-0</pub-id></element-citation></ref><ref id="bib0020"><label>4&#8226;&#8226;</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name name-style="western"><surname>Hadjadj</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yatim</surname><given-names>N.</given-names></name><name name-style="western"><surname>Barnabei</surname><given-names>L.</given-names></name><name name-style="western"><surname>Corneau</surname><given-names>A.</given-names></name><name name-style="western"><surname>Boussier</surname><given-names>J.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pere</surname><given-names>H.</given-names></name><name name-style="western"><surname>Charbit</surname><given-names>B.</given-names></name><name name-style="western"><surname>Bondet</surname><given-names>V.</given-names></name><name name-style="western"><surname>Chenevier-Gobeaux</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients</article-title><source>Science</source><volume>369</volume><year>2020</year><fpage>718</fpage><lpage>724</lpage><pub-id pub-id-type="pmid">32661059</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abc6027</pub-id><pub-id pub-id-type="pmcid">PMC7402632</pub-id></element-citation><note><p>Hadjadj&#160;<italic toggle="yes">et al.</italic> reveal a clear role for dampened Type I IFN signaling in driving COVID-19 disease pathology. Using an integrated immune analysis of 50 patients with COVID-19, they discovered that patients with severe and critical disease had significantly dampened IFN&#945; and IFN&#946; responses. Accompanying this reduced interferon signaling was augmented inflammation via NF-&#954;B.</p></note></ref><ref id="bib0025"><label>5</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name name-style="western"><surname>Tang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ji</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>C.</given-names></name></person-group><article-title>Cytokine storm in COVID-19: the current evidence and treatment strategies</article-title><source>Front Immunol</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">1708</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.01708</pub-id><pub-id pub-id-type="pmcid">PMC7365923</pub-id><pub-id pub-id-type="pmid">32754163</pub-id></element-citation></ref><ref id="bib0030"><label>6</label><element-citation publication-type="journal" id="sbref0030"><person-group person-group-type="author"><name name-style="western"><surname>Carsana</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sonzogni</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nasr</surname><given-names>A.</given-names></name><name name-style="western"><surname>Rossi</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Pellegrinelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Zerbi</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rech</surname><given-names>R.</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Antinori</surname><given-names>S.</given-names></name><name name-style="western"><surname>Corbellino</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study</article-title><source>Lancet Infect Dis</source><volume>20</volume><year>2020</year><fpage>1135</fpage><lpage>1140</lpage><pub-id pub-id-type="pmid">32526193</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30434-5</pub-id><pub-id pub-id-type="pmcid">PMC7279758</pub-id></element-citation></ref><ref id="bib0035"><label>7</label><element-citation publication-type="journal" id="sbref0035"><person-group person-group-type="author"><name name-style="western"><surname>Fourati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Tomalin</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Mule</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Chawla</surname><given-names>D.</given-names></name><name name-style="western"><surname>Gerriitsen</surname><given-names>B.</given-names></name><name name-style="western"><surname>Rychkov</surname><given-names>D.</given-names></name><name name-style="western"><surname>Henrich</surname><given-names>E.</given-names></name><name name-style="western"><surname>Miller</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hagain</surname><given-names>T.</given-names></name><name name-style="western"><surname>Diray-Arce</surname><given-names>J.</given-names></name><etal/></person-group><article-title>An innate immune activation state prior to vaccination predicts responsiveness to multiple vaccines</article-title><source>bioRxiv</source><year>2021</year></element-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name name-style="western"><surname>Hou</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>D.</given-names></name><name name-style="western"><surname>Carpp</surname><given-names>L.N.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>T.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Jia</surname><given-names>M.</given-names></name><name name-style="western"><surname>Peng</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Early pro-inflammatory signal and T-cell activation associate with vaccine-induced anti-vaccinia protective neutralizing antibodies</article-title><source>Front Immunol</source><volume>12</volume><year>2021</year><object-id pub-id-type="publisher-id">737487</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2021.737487</pub-id><pub-id pub-id-type="pmcid">PMC8542877</pub-id><pub-id pub-id-type="pmid">34707608</pub-id></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name name-style="western"><surname>Nakayama</surname><given-names>T.</given-names></name></person-group><article-title>An inflammatory response is essential for the development of adaptive immunity-immunogenicity and immunotoxicity</article-title><source>Vaccine</source><volume>34</volume><year>2016</year><fpage>5815</fpage><lpage>5818</lpage><pub-id pub-id-type="pmid">27745952</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.vaccine.2016.08.051</pub-id></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name name-style="western"><surname>Qin</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cha</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Neelapu</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.J.</given-names></name><name name-style="western"><surname>Kwak</surname><given-names>L.W.</given-names></name></person-group><article-title>Vaccine site inflammation potentiates idiotype DNA vaccine-induced therapeutic T cell-, and not B cell-, dependent antilymphoma immunity</article-title><source>Blood</source><volume>114</volume><year>2009</year><fpage>4142</fpage><lpage>4149</lpage><pub-id pub-id-type="pmid">19749091</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood-2009-05-219683</pub-id></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>H.M.</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B.</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K.</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S.</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R.</given-names></name><name name-style="western"><surname>Diemert</surname><given-names>D.</given-names></name><name name-style="western"><surname>Spector</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.</given-names></name><name name-style="western"><surname>Creech</surname><given-names>C.B.</given-names></name><etal/></person-group><article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title><source>N Engl J Med</source><volume>384</volume><year>2021</year><fpage>403</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N.</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A.</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S.</given-names></name><name name-style="western"><surname>Perez</surname><given-names>J.L.</given-names></name><name name-style="western"><surname>Perez Marc</surname><given-names>G.</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>E.D.</given-names></name><name name-style="western"><surname>Zerbini</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title><source>N Engl J Med</source><volume>383</volume><year>2020</year><fpage>2603</fpage><lpage>2615</lpage><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name name-style="western"><surname>Sadoff</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gray</surname><given-names>G.</given-names></name><name name-style="western"><surname>Vandebosch</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cardenas</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shukarev</surname><given-names>G.</given-names></name><name name-style="western"><surname>Grinsztejn</surname><given-names>B.</given-names></name><name name-style="western"><surname>Goepfert</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Truyers</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fennema</surname><given-names>H.</given-names></name><name name-style="western"><surname>Spiessens</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19</article-title><source>N Engl J Med</source><volume>384</volume><year>2021</year><fpage>2187</fpage><lpage>2201</lpage><pub-id pub-id-type="pmid">33882225</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2101544</pub-id><pub-id pub-id-type="pmcid">PMC8220996</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Clemens</surname><given-names>S.A.C.</given-names></name><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Weckx</surname><given-names>L.Y.</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>P.M.</given-names></name><name name-style="western"><surname>Aley</surname><given-names>P.K.</given-names></name><name name-style="western"><surname>Angus</surname><given-names>B.</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>V.L.</given-names></name><name name-style="western"><surname>Barnabas</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Bhorat</surname><given-names>Q.E.</given-names></name><etal/></person-group><article-title>Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK</article-title><source>Lancet</source><volume>397</volume><year>2021</year><fpage>99</fpage><lpage>111</lpage><pub-id pub-id-type="pmid">33306989</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S0140-6736(20)32661-1</pub-id><pub-id pub-id-type="pmcid">PMC7723445</pub-id></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>G.F.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lou</surname><given-names>Z.</given-names></name><etal/></person-group><article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title><source>Lancet Infect Dis</source><volume>21</volume><year>2021</year><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zeng</surname><given-names>G.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chu</surname><given-names>K.</given-names></name><name name-style="western"><surname>Han</surname><given-names>W.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Yin</surname><given-names>W.</given-names></name><etal/></person-group><article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title><source>Lancet Infect Dis</source><volume>21</volume><year>2021</year><fpage>181</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">33217362</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(20)30843-4</pub-id><pub-id pub-id-type="pmcid">PMC7832443</pub-id></element-citation></ref><ref id="bib0085"><label>17&#8226;&#8226;</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name name-style="western"><surname>Lopez Bernal</surname><given-names>J.</given-names></name><name name-style="western"><surname>Andrews</surname><given-names>N.</given-names></name><name name-style="western"><surname>Gower</surname><given-names>C.</given-names></name><name name-style="western"><surname>Gallagher</surname><given-names>E.</given-names></name><name name-style="western"><surname>Simmons</surname><given-names>R.</given-names></name><name name-style="western"><surname>Thelwall</surname><given-names>S.</given-names></name><name name-style="western"><surname>Stowe</surname><given-names>J.</given-names></name><name name-style="western"><surname>Tessier</surname><given-names>E.</given-names></name><name name-style="western"><surname>Groves</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dabrera</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant</article-title><source>N Engl J Med</source><volume>385</volume><year>2021</year><fpage>585</fpage><lpage>594</lpage><pub-id pub-id-type="pmid">34289274</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2108891</pub-id><pub-id pub-id-type="pmcid">PMC8314739</pub-id></element-citation><note><p>Of great importance to current events, Bernal&#160;<italic toggle="yes">et al.</italic> investigated the effectiveness of the BNT162b2 and ChAdOx1 vaccines against the emergent B.1.617.2 delta variant SARS-CoV-2. They show in this cohort of patients that efficacy of the BNT162b2 vaccine drops from 93.7% for the alpha variant to 88% with the delta variant. For ChAdOx1 efficacy from 74.5% for the alpha variant but only 67% for the delta variant. Efficacy after a single dose was also reduced from 48.7% to 30.7%. This study highlights that the delta variant, and likely other future variants, will more readily escape vaccine mediate protection.</p></note></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name name-style="western"><surname>Madhi</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Baillie</surname><given-names>V.</given-names></name><name name-style="western"><surname>Cutland</surname><given-names>C.L.</given-names></name><name name-style="western"><surname>Voysey</surname><given-names>M.</given-names></name><name name-style="western"><surname>Koen</surname><given-names>A.L.</given-names></name><name name-style="western"><surname>Fairlie</surname><given-names>L.</given-names></name><name name-style="western"><surname>Padayachee</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>Dheda</surname><given-names>K.</given-names></name><name name-style="western"><surname>Barnabas</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Bhorat</surname><given-names>Q.E.</given-names></name><etal/></person-group><article-title>Efficacy of the ChAdOx1 nCoV-19 Covid-19 vaccine against the B.1.351 variant</article-title><source>N Engl J Med</source><volume>384</volume><year>2021</year><fpage>1885</fpage><lpage>1898</lpage><pub-id pub-id-type="pmid">33725432</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2102214</pub-id><pub-id pub-id-type="pmcid">PMC7993410</pub-id></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name name-style="western"><surname>Hacisuleyman</surname><given-names>E.</given-names></name><name name-style="western"><surname>Hale</surname><given-names>C.</given-names></name><name name-style="western"><surname>Saito</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Blachere</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Bergh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Conlon</surname><given-names>E.G.</given-names></name><name name-style="western"><surname>Schaefer-Babajew</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>DaSilva</surname><given-names>J.</given-names></name><name name-style="western"><surname>Muecksch</surname><given-names>F.</given-names></name><name name-style="western"><surname>Gaebler</surname><given-names>C.</given-names></name><etal/></person-group><article-title>Vaccine breakthrough infections with SARS-CoV-2 variants</article-title><source>N Engl J Med</source><volume>384</volume><year>2021</year><fpage>2212</fpage><lpage>2218</lpage><pub-id pub-id-type="pmid">33882219</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMoa2105000</pub-id><pub-id pub-id-type="pmcid">PMC8117968</pub-id></element-citation></ref><ref id="bib0100"><label>20&#8226;&#8226;</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name name-style="western"><surname>Garcia-Beltran</surname><given-names>W.F.</given-names></name><name name-style="western"><surname>Lam</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>St Denis</surname><given-names>K.</given-names></name><name name-style="western"><surname>Nitido</surname><given-names>A.D.</given-names></name><name name-style="western"><surname>Garcia</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Hauser</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Feldman</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pavlovic</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Gregory</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Poznansky</surname><given-names>M.C.</given-names></name><etal/></person-group><article-title>Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity</article-title><source>Cell</source><volume>184</volume><year>2021</year><fpage>2523</fpage><pub-id pub-id-type="pmid">33930298</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.04.006</pub-id><pub-id pub-id-type="pmcid">PMC8082941</pub-id></element-citation><note><p>In this study, Garcia-Beltran&#160;<italic toggle="yes">et al.</italic> test the efficacy of antibodies from 99 vaccinated individuals to neutralize 10 of the most common SARS-CoV-2 variants. They discover that five of these variants show potent resistance to neutralization including RBD mutants K417N/T, EE484K and N501Y. Neutralization of B.1.351 variants was similar to the original SARS-CoV virus.</p></note></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name name-style="western"><surname>Pegu</surname><given-names>A.</given-names></name><name name-style="western"><surname>O&#8217;Connell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schmidt</surname><given-names>S.D.</given-names></name><name name-style="western"><surname>O&#8217;Dell</surname><given-names>S.</given-names></name><name name-style="western"><surname>Talana</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Anderson</surname><given-names>E.</given-names></name><name name-style="western"><surname>Bennett</surname><given-names>H.</given-names></name><name name-style="western"><surname>Corbett</surname><given-names>K.S.</given-names></name><etal/></person-group><article-title>Durability of mRNA-1273-induced antibodies against SARS-CoV-2 variants</article-title><source>bioRxiv</source><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/science.abj4176</pub-id><pub-id pub-id-type="pmcid">PMC8691522</pub-id><pub-id pub-id-type="pmid">34385356</pub-id></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Pinsky</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Suthar</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davis-Gardner</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>K.</given-names></name><name name-style="western"><surname>Flowers</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Wrammert</surname><given-names>J.</given-names></name><name name-style="western"><surname>Hussaini</surname><given-names>L.</given-names></name><name name-style="western"><surname>Ciric</surname><given-names>C.R.</given-names></name><etal/></person-group><article-title>Infection and vaccine-induced neutralizing-antibody responses to the SARS-CoV-2 B.1.617 variants</article-title><source>N Engl J Med</source><volume>385</volume><year>2021</year><fpage>664</fpage><lpage>666</lpage><pub-id pub-id-type="pmid">34233096</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1056/NEJMc2107799</pub-id><pub-id pub-id-type="pmcid">PMC8279090</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Norwood</surname><given-names>C.</given-names></name><name name-style="western"><surname>Floyd</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Davis-Gardner</surname><given-names>M.E.</given-names></name><name name-style="western"><surname>Hudson</surname><given-names>W.H.</given-names></name><name name-style="western"><surname>Mantus</surname><given-names>G.</given-names></name><name name-style="western"><surname>Nyhoff</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Adelman</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>Fineman</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant</article-title><source>Cell Host Microbe</source><volume>29</volume><year>2021</year><fpage>516</fpage><lpage>521.e3</lpage><pub-id pub-id-type="pmid">33798491</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2021.03.009</pub-id><pub-id pub-id-type="pmcid">PMC7980225</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name name-style="western"><surname>Messali</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bertelli</surname><given-names>A.</given-names></name><name name-style="western"><surname>Campisi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ciccozzi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Caruso</surname><given-names>A.</given-names></name><name name-style="western"><surname>Caccuri</surname><given-names>F.</given-names></name></person-group><article-title>A cluster of the new SARS-CoV-2 B.1.621 lineage in Italy and sensitivity of the viral isolate to the BNT162b2 vaccine</article-title><source>J Med Virol</source><volume>93</volume><year>2021</year><fpage>6468</fpage><lpage>6470</lpage><pub-id pub-id-type="pmid">34329486</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.27247</pub-id><pub-id pub-id-type="pmcid">PMC8426698</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><element-citation publication-type="journal" id="sbref0125"><person-group person-group-type="author"><name name-style="western"><surname>Mostaghimi</surname><given-names>D.</given-names></name><name name-style="western"><surname>Valdez</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>Larson</surname><given-names>H.T.</given-names></name><name name-style="western"><surname>Kalinich</surname><given-names>C.C.</given-names></name><name name-style="western"><surname>Iwasaki</surname><given-names>A.</given-names></name></person-group><article-title>Prevention of host-to-host transmission by SARS-CoV-2 vaccines</article-title><source>Lancet Infect Dis</source><volume>21</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S1473-3099(21)00472-2</pub-id><pub-id pub-id-type="pmcid">PMC8439617</pub-id><pub-id pub-id-type="pmid">34534512</pub-id></element-citation></ref><ref id="bib0130"><label>26&#8226;&#8226;</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Walls</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Golden</surname><given-names>N.</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Fischinger</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Aye</surname><given-names>P.</given-names></name><name name-style="western"><surname>Navarro</surname><given-names>M.J.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><etal/></person-group><article-title>Adjuvanting a subunit COVID-19 vaccine to induce protective immunity</article-title><source>Nature</source><volume>594</volume><year>2021</year><fpage>253</fpage><lpage>258</lpage><pub-id pub-id-type="pmid">33873199</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03530-2</pub-id></element-citation><note><p>In line with the focus of this review, Arunachalam&#160;<italic toggle="yes">et al.</italic> recently showed that the use of different adjuvants modulated the neutralizing and cross-neutralizing Ab responses in NHP receiving a protein subunit vaccine. The authors tested five different adjuvants: O/W 1849101, AS03, AS37, CpG1018-alum and alum. They found that all adjuvants except for O/W were able to induce neutralizing Ab titers and conferred protection from SARS-CoV-2 challenge. Adjuvant choice also impacted on the levels of cross-neutralizing antibodies functional against the B.1.351 variant. These data clearly highlight that adjuvant choice impacts on the nature, magnitude and potentially durability of COVIID-19 vaccine responses.</p></note></ref><ref id="bib0135"><label>27</label><element-citation publication-type="journal" id="sbref0135"><person-group person-group-type="author"><name name-style="western"><surname>Tomalka</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Pelletier</surname><given-names>A.N.</given-names></name><name name-style="western"><surname>Fourati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Latif</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A.</given-names></name><name name-style="western"><surname>Furr</surname><given-names>K.</given-names></name><name name-style="western"><surname>Carlson</surname><given-names>K.</given-names></name><name name-style="western"><surname>Lifton</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Wilkinson</surname><given-names>P.</given-names></name><etal/></person-group><article-title>The transcription factor CREB1 is a mechanistic driver of immunogenicity and reduced HIV-1 acquisition following ALVAC vaccination</article-title><source>Nat Immunol</source><volume>22</volume><year>2021</year><fpage>1294</fpage><lpage>1305</lpage><pub-id pub-id-type="pmid">34556879</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-021-01026-9</pub-id><pub-id pub-id-type="pmcid">PMC8525330</pub-id></element-citation></ref><ref id="bib0140"><label>28&#8226;</label><element-citation publication-type="journal" id="sbref0140"><person-group person-group-type="author"><name name-style="western"><surname>Vaccari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Fourati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Schifanella</surname><given-names>L.</given-names></name><name name-style="western"><surname>Liyanage</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Cameron</surname><given-names>M.</given-names></name><name name-style="western"><surname>Keele</surname><given-names>B.F.</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X.</given-names></name><name name-style="western"><surname>Tomaras</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Billings</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition</article-title><source>Nat Med</source><volume>22</volume><year>2016</year><fpage>762</fpage><lpage>770</lpage><pub-id pub-id-type="pmid">27239761</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nm.4105</pub-id><pub-id pub-id-type="pmcid">PMC5916782</pub-id></element-citation><note><p>This paper is crucial in identifying that the nature of the adjuvant included in a vaccination has a profound impact on efficacy and protection. In this study, the authors show that ALVAC vaccination with the adjuvant Alum is protective from SIV infection while ALVAC vaccination with the adjuvant MF59 is not protective. Though MF59 is itself a potent adjuvant and has been shown to enhanced humoral immune responses, in this vaccine platform its inclusion proved deleterious compared to Alum. This highlights the point that one size does not fit all when it comes to vaccines and adjuvants.</p></note></ref><ref id="bib0145"><label>29</label><element-citation publication-type="journal" id="sbref0145"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>Niels Peter H.</given-names></name><name name-style="western"><surname>Olsen</surname><given-names>Anja</given-names></name><name name-style="western"><surname>Buonsanti</surname><given-names>Cecilia</given-names></name><name name-style="western"><surname>Follmann</surname><given-names>Frank</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Yuan</given-names></name><name name-style="western"><surname>Coler</surname><given-names>Rhea N.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>Christopher B.</given-names></name><name name-style="western"><surname>Meinke</surname><given-names>Andreas</given-names></name><name name-style="western"><surname>D'Oro</surname><given-names>Ugo</given-names></name><name name-style="western"><surname>Casini</surname><given-names>Daniele</given-names></name><etal/></person-group><article-title>Different human vaccine adjuvants promote distinct antigen-independent immunological signatures tailored to different pathogens</article-title><source>Sci Rep</source><volume>6</volume><year>2016</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/srep19570</pub-id><pub-id pub-id-type="pmcid">PMC4726129</pub-id><pub-id pub-id-type="pmid">26791076</pub-id></element-citation></ref><ref id="bib0150"><label>30</label><element-citation publication-type="journal" id="sbref0150"><person-group person-group-type="author"><name name-style="western"><surname>Acharya</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gack</surname><given-names>M.U.</given-names></name></person-group><article-title>Dysregulation of type I interferon responses in COVID-19</article-title><source>Nat Rev Immunol</source><volume>20</volume><year>2020</year><fpage>397</fpage><lpage>398</lpage><pub-id pub-id-type="pmid">32457522</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0346-x</pub-id><pub-id pub-id-type="pmcid">PMC7249038</pub-id></element-citation></ref><ref id="bib0155"><label>31</label><element-citation publication-type="journal" id="sbref0155"><person-group person-group-type="author"><name name-style="western"><surname>Sa Ribero</surname><given-names>M.</given-names></name><name name-style="western"><surname>Jouvenet</surname><given-names>N.</given-names></name><name name-style="western"><surname>Dreux</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nisole</surname><given-names>S.</given-names></name></person-group><article-title>Interplay between SARS-CoV-2 and the type I interferon response</article-title><source>PLoS Pathog</source><volume>16</volume><year>2020</year><object-id pub-id-type="publisher-id">e1008737</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1008737</pub-id><pub-id pub-id-type="pmcid">PMC7390284</pub-id><pub-id pub-id-type="pmid">32726355</pub-id></element-citation></ref><ref id="bib0160"><label>32&#8226;&#8226;</label><element-citation publication-type="journal" id="sbref0160"><person-group person-group-type="author"><name name-style="western"><surname>Blanco-Melo</surname><given-names>D.</given-names></name><name name-style="western"><surname>Nilsson-Payant</surname><given-names>B.E.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>W.C.</given-names></name><name name-style="western"><surname>Uhl</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hoagland</surname><given-names>D.</given-names></name><name name-style="western"><surname>Moller</surname><given-names>R.</given-names></name><name name-style="western"><surname>Jordan</surname><given-names>T.X.</given-names></name><name name-style="western"><surname>Oishi</surname><given-names>K.</given-names></name><name name-style="western"><surname>Panis</surname><given-names>M.</given-names></name><name name-style="western"><surname>Sachs</surname><given-names>D.</given-names></name><etal/></person-group><article-title>Imbalanced host response to SARS-CoV-2 drives development of COVID-19</article-title><source>Cell</source><volume>181</volume><year>2020</year><fpage>1036</fpage><lpage>1045.e9</lpage><pub-id pub-id-type="pmid">32416070</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2020.04.026</pub-id><pub-id pub-id-type="pmcid">PMC7227586</pub-id></element-citation><note><p>In this study, Blanco-Melo&#160;<italic toggle="yes">et al.</italic> demonstrate that dampened interferons are a feature of SARS-CoV-2 infection <italic toggle="yes">in vitro</italic>, in mice and in humans. Importantly, they show that immortalized lung epithelial cells lines and human bronchial epithelial cells have dampened induction of interferons. This data suggests that defective interferon signaling occurs as early as initial sensing by infected epithelial cells.</p></note></ref><ref id="bib0165"><label>33</label><element-citation publication-type="journal" id="sbref0165"><person-group person-group-type="author"><name name-style="western"><surname>Galani</surname><given-names>I.E.</given-names></name><name name-style="western"><surname>Rovina</surname><given-names>N.</given-names></name><name name-style="western"><surname>Lampropoulou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Triantafyllia</surname><given-names>V.</given-names></name><name name-style="western"><surname>Manioudaki</surname><given-names>M.</given-names></name><name name-style="western"><surname>Pavlos</surname><given-names>E.</given-names></name><name name-style="western"><surname>Koukaki</surname><given-names>E.</given-names></name><name name-style="western"><surname>Fragkou</surname><given-names>P.C.</given-names></name><name name-style="western"><surname>Panou</surname><given-names>V.</given-names></name><name name-style="western"><surname>Rapti</surname><given-names>V.</given-names></name><etal/></person-group><article-title>Untuned antiviral immunity in COVID-19 revealed by temporal type I/III interferon patterns and flu comparison</article-title><source>Nat Immunol</source><volume>22</volume><year>2021</year><fpage>32</fpage><lpage>40</lpage><pub-id pub-id-type="pmid">33277638</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-020-00840-x</pub-id></element-citation></ref><ref id="bib0170"><label>34</label><element-citation publication-type="journal" id="sbref0170"><person-group person-group-type="author"><name name-style="western"><surname>Alavi Darazam</surname><given-names>I.</given-names></name><name name-style="western"><surname>Shokouhi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pourhoseingholi</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Naghibi Irvani</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Mokhtari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Shabani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Amirdosara</surname><given-names>M.</given-names></name><name name-style="western"><surname>Torabinavid</surname><given-names>P.</given-names></name><name name-style="western"><surname>Golmohammadi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Hashemi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Role of interferon therapy in severe COVID-19: the COVIFERON randomized controlled trial</article-title><source>Sci Rep</source><volume>11</volume><year>2021</year><object-id pub-id-type="publisher-id">8059</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41598-021-86859-y</pub-id><pub-id pub-id-type="pmcid">PMC8044200</pub-id><pub-id pub-id-type="pmid">33850184</pub-id></element-citation></ref><ref id="bib0175"><label>35</label><element-citation publication-type="journal" id="sbref0175"><person-group person-group-type="author"><name name-style="western"><surname>Monk</surname><given-names>P.D.</given-names></name><name name-style="western"><surname>Marsden</surname><given-names>R.J.</given-names></name><name name-style="western"><surname>Tear</surname><given-names>V.J.</given-names></name><name name-style="western"><surname>Brookes</surname><given-names>J.</given-names></name><name name-style="western"><surname>Batten</surname><given-names>T.N.</given-names></name><name name-style="western"><surname>Mankowski</surname><given-names>M.</given-names></name><name name-style="western"><surname>Gabbay</surname><given-names>F.J.</given-names></name><name name-style="western"><surname>Davies</surname><given-names>D.E.</given-names></name><name name-style="western"><surname>Holgate</surname><given-names>S.T.</given-names></name><name name-style="western"><surname>Ho</surname><given-names>L.P.</given-names></name><etal/></person-group><article-title>Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial</article-title><source>Lancet Respir Med</source><volume>9</volume><year>2021</year><fpage>196</fpage><lpage>206</lpage><pub-id pub-id-type="pmid">33189161</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/S2213-2600(20)30511-7</pub-id><pub-id pub-id-type="pmcid">PMC7836724</pub-id></element-citation></ref><ref id="bib0180"><label>36</label><element-citation publication-type="journal" id="sbref0180"><person-group person-group-type="author"><name name-style="western"><surname>Zhou</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>V.</given-names></name><name name-style="western"><surname>Shannon</surname><given-names>C.P.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>X.S.</given-names></name><name name-style="western"><surname>Xiang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Z.H.</given-names></name><name name-style="western"><surname>Tebbutt</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Kollmann</surname><given-names>T.R.</given-names></name><name name-style="western"><surname>Fish</surname><given-names>E.N.</given-names></name></person-group><article-title>Interferon-alpha2b treatment for COVID-19</article-title><source>Front Immunol</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">1061</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.01061</pub-id><pub-id pub-id-type="pmcid">PMC7242746</pub-id><pub-id pub-id-type="pmid">32574262</pub-id></element-citation></ref><ref id="bib0185"><label>37</label><element-citation publication-type="journal" id="sbref0185"><person-group person-group-type="author"><name name-style="western"><surname>Burke</surname><given-names>T.P.</given-names></name><name name-style="western"><surname>Engstrom</surname><given-names>P.</given-names></name><name name-style="western"><surname>Chavez</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Fonbuena</surname><given-names>J.A.</given-names></name><name name-style="western"><surname>Vance</surname><given-names>R.E.</given-names></name><name name-style="western"><surname>Welch</surname><given-names>M.D.</given-names></name></person-group><article-title>Inflammasome-mediated antagonism of type I interferon enhances Rickettsia pathogenesis</article-title><source>Nat Microbiol</source><volume>5</volume><year>2020</year><fpage>688</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">32123346</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41564-020-0673-5</pub-id><pub-id pub-id-type="pmcid">PMC7239376</pub-id></element-citation></ref><ref id="bib0190"><label>38</label><element-citation publication-type="journal" id="sbref0190"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Ning</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>P.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Sha</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lv</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>X.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Fang</surname><given-names>R.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>G.</given-names></name><etal/></person-group><article-title>Inflammasome activation triggers caspase-1-mediated cleavage of cGAS to regulate responses to DNA virus infection</article-title><source>Immunity</source><volume>46</volume><year>2017</year><fpage>393</fpage><lpage>404</lpage><pub-id pub-id-type="pmid">28314590</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2017.02.011</pub-id></element-citation></ref><ref id="bib0195"><label>39</label><element-citation publication-type="journal" id="sbref0195"><person-group person-group-type="author"><name name-style="western"><surname>Guarda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Braun</surname><given-names>M.</given-names></name><name name-style="western"><surname>Staehli</surname><given-names>F.</given-names></name><name name-style="western"><surname>Tardivel</surname><given-names>A.</given-names></name><name name-style="western"><surname>Mattmann</surname><given-names>C.</given-names></name><name name-style="western"><surname>Forster</surname><given-names>I.</given-names></name><name name-style="western"><surname>Farlik</surname><given-names>M.</given-names></name><name name-style="western"><surname>Decker</surname><given-names>T.</given-names></name><name name-style="western"><surname>Du Pasquier</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Romero</surname><given-names>P.</given-names></name><etal/></person-group><article-title>Type I interferon inhibits interleukin-1 production and inflammasome activation</article-title><source>Immunity</source><volume>34</volume><year>2011</year><fpage>213</fpage><lpage>223</lpage><pub-id pub-id-type="pmid">21349431</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2011.02.006</pub-id></element-citation></ref><ref id="bib0200"><label>40</label><element-citation publication-type="journal" id="sbref0200"><person-group person-group-type="author"><name name-style="western"><surname>Sha</surname><given-names>W.</given-names></name><name name-style="western"><surname>Mitoma</surname><given-names>H.</given-names></name><name name-style="western"><surname>Hanabuchi</surname><given-names>S.</given-names></name><name name-style="western"><surname>Bao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Sugimoto</surname><given-names>N.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zhong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>B.</given-names></name><etal/></person-group><article-title>Human NLRP3 inflammasome senses multiple types of bacterial RNAs</article-title><source>Proc Natl Acad Sci U S A</source><volume>111</volume><year>2014</year><fpage>16059</fpage><lpage>16064</lpage><pub-id pub-id-type="pmid">25355909</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.1412487111</pub-id><pub-id pub-id-type="pmcid">PMC4234566</pub-id></element-citation></ref><ref id="bib0205"><label>41</label><element-citation publication-type="journal" id="sbref0205"><person-group person-group-type="author"><name name-style="western"><surname>Costa</surname><given-names>A.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>R.</given-names></name><name name-style="western"><surname>Signorino</surname><given-names>G.</given-names></name><name name-style="western"><surname>Malara</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cardile</surname><given-names>F.</given-names></name><name name-style="western"><surname>Biondo</surname><given-names>C.</given-names></name><name name-style="western"><surname>Midiri</surname><given-names>A.</given-names></name><name name-style="western"><surname>Galbo</surname><given-names>R.</given-names></name><name name-style="western"><surname>Trieu-Cuot</surname><given-names>P.</given-names></name><name name-style="western"><surname>Papasergi</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Activation of the NLRP3 inflammasome by group B streptococci</article-title><source>J Immunol</source><volume>188</volume><year>2012</year><fpage>1953</fpage><lpage>1960</lpage><pub-id pub-id-type="pmid">22250086</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1102543</pub-id><pub-id pub-id-type="pmcid">PMC3273589</pub-id></element-citation></ref><ref id="bib0210"><label>42</label><element-citation publication-type="journal" id="sbref0210"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Gong</surname><given-names>Y.N.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>F.</given-names></name></person-group><article-title>The NLRC4 inflammasome receptors for bacterial flagellin and type III secretion apparatus</article-title><source>Nature</source><volume>477</volume><year>2011</year><fpage>596</fpage><lpage>600</lpage><pub-id pub-id-type="pmid">21918512</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature10510</pub-id></element-citation></ref><ref id="bib0215"><label>43</label><element-citation publication-type="journal" id="sbref0215"><person-group person-group-type="author"><name name-style="western"><surname>Franchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Amer</surname><given-names>A.</given-names></name><name name-style="western"><surname>Body-Malapel</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Ozoren</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jagirdar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Inohara</surname><given-names>N.</given-names></name><name name-style="western"><surname>Vandenabeele</surname><given-names>P.</given-names></name><name name-style="western"><surname>Bertin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Coyle</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Cytosolic flagellin requires Ipaf for activation of caspase-1 and interleukin 1beta in salmonella-infected macrophages</article-title><source>Nat Immunol</source><volume>7</volume><year>2006</year><fpage>576</fpage><lpage>582</lpage><pub-id pub-id-type="pmid">16648852</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni1346</pub-id></element-citation></ref><ref id="bib0220"><label>44</label><element-citation publication-type="journal" id="sbref0220"><person-group person-group-type="author"><name name-style="western"><surname>Miao</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Ernst</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Dors</surname><given-names>M.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>D.P.</given-names></name><name name-style="western"><surname>Aderem</surname><given-names>A.</given-names></name></person-group><article-title>Pseudomonas aeruginosa activates caspase 1 through Ipaf</article-title><source>Proc Natl Acad Sci U S A</source><volume>105</volume><year>2008</year><fpage>2562</fpage><lpage>2567</lpage><pub-id pub-id-type="pmid">18256184</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1073/pnas.0712183105</pub-id><pub-id pub-id-type="pmcid">PMC2268176</pub-id></element-citation></ref><ref id="bib0225"><label>45</label><element-citation publication-type="journal" id="sbref0225"><person-group person-group-type="author"><name name-style="western"><surname>Hise</surname><given-names>A.G.</given-names></name><name name-style="western"><surname>Tomalka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ganesan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name></person-group><article-title>An essential role for the NLRP3 inflammasome in host defense against the human fungal pathogen <italic toggle="yes">Candida albicans</italic></article-title><source>Cell Host Microbe</source><volume>5</volume><year>2009</year><fpage>487</fpage><lpage>497</lpage><pub-id pub-id-type="pmid">19454352</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.chom.2009.05.002</pub-id><pub-id pub-id-type="pmcid">PMC2824856</pub-id></element-citation></ref><ref id="bib0230"><label>46</label><element-citation publication-type="journal" id="sbref0230"><person-group person-group-type="author"><name name-style="western"><surname>Tomalka</surname><given-names>J.</given-names></name><name name-style="western"><surname>Ganesan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Azodi</surname><given-names>E.</given-names></name><name name-style="western"><surname>Patel</surname><given-names>K.</given-names></name><name name-style="western"><surname>Majmudar</surname><given-names>P.</given-names></name><name name-style="western"><surname>Hall</surname><given-names>B.A.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Hise</surname><given-names>A.G.</given-names></name></person-group><article-title>A novel role for the NLRC4 inflammasome in mucosal defenses against the fungal pathogen <italic toggle="yes">Candida albicans</italic></article-title><source>PLoS Pathog</source><volume>7</volume><year>2011</year><object-id pub-id-type="publisher-id">e1002379</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.ppat.1002379</pub-id><pub-id pub-id-type="pmcid">PMC3234225</pub-id><pub-id pub-id-type="pmid">22174673</pub-id></element-citation></ref><ref id="bib0235"><label>47</label><element-citation publication-type="journal" id="sbref0235"><person-group person-group-type="author"><name name-style="western"><surname>Said-Sadier</surname><given-names>N.</given-names></name><name name-style="western"><surname>Padilla</surname><given-names>E.</given-names></name><name name-style="western"><surname>Langsley</surname><given-names>G.</given-names></name><name name-style="western"><surname>Ojcius</surname><given-names>D.M.</given-names></name></person-group><article-title><italic toggle="yes">Aspergillus fumigatus</italic> stimulates the NLRP3 inflammasome through a pathway requiring ROS production and the Syk tyrosine kinase</article-title><source>PLoS One</source><volume>5</volume><year>2010</year><object-id pub-id-type="publisher-id">e10008</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0010008</pub-id><pub-id pub-id-type="pmcid">PMC2848854</pub-id><pub-id pub-id-type="pmid">20368800</pub-id></element-citation></ref><ref id="bib0240"><label>48</label><element-citation publication-type="journal" id="sbref0240"><person-group person-group-type="author"><name name-style="western"><surname>Kelley</surname><given-names>N.</given-names></name><name name-style="western"><surname>Jeltema</surname><given-names>D.</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>He</surname><given-names>Y.</given-names></name></person-group><article-title>The NLRP3 inflammasome: an overview of mechanisms of activation and regulation</article-title><source>Int J Mol Sci</source><volume>20</volume><year>2019</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/ijms20133328</pub-id><pub-id pub-id-type="pmcid">PMC6651423</pub-id><pub-id pub-id-type="pmid">31284572</pub-id></element-citation></ref><ref id="bib0245"><label>49</label><element-citation publication-type="journal" id="sbref0245"><person-group person-group-type="author"><name name-style="western"><surname>Martinon</surname><given-names>F.</given-names></name></person-group><article-title>Signaling by ROS drives inflammasome activation</article-title><source>Eur J Immunol</source><volume>40</volume><year>2010</year><fpage>616</fpage><lpage>619</lpage><pub-id pub-id-type="pmid">20201014</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.200940168</pub-id></element-citation></ref><ref id="bib0250"><label>50</label><element-citation publication-type="journal" id="sbref0250"><person-group person-group-type="author"><name name-style="western"><surname>Lugrin</surname><given-names>J.</given-names></name><name name-style="western"><surname>Martinon</surname><given-names>F.</given-names></name></person-group><article-title>The AIM2 inflammasome: sensor of pathogens and cellular perturbations</article-title><source>Immunol Rev</source><volume>281</volume><year>2018</year><fpage>99</fpage><lpage>114</lpage><pub-id pub-id-type="pmid">29247998</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imr.12618</pub-id></element-citation></ref><ref id="bib0255"><label>51</label><element-citation publication-type="journal" id="sbref0255"><person-group person-group-type="author"><name name-style="western"><surname>Rathinam</surname><given-names>V.A.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Waggoner</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S.</given-names></name><name name-style="western"><surname>Cole</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Waggoner</surname><given-names>L.</given-names></name><name name-style="western"><surname>Vanaja</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Monks</surname><given-names>B.G.</given-names></name><name name-style="western"><surname>Ganesan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Latz</surname><given-names>E.</given-names></name><etal/></person-group><article-title>The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses</article-title><source>Nat Immunol</source><volume>11</volume><year>2010</year><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">20351692</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.1864</pub-id><pub-id pub-id-type="pmcid">PMC2887480</pub-id></element-citation></ref><ref id="bib0260"><label>52</label><element-citation publication-type="journal" id="sbref0260"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Alcorn</surname><given-names>J.F.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>S.</given-names></name><name name-style="western"><surname>Pilewski</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>A.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kolls</surname><given-names>J.K.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J.</given-names></name></person-group><article-title>AIM2 inflammasome is critical for influenza-induced lung injury and mortality</article-title><source>J Immunol</source><volume>198</volume><year>2017</year><fpage>4383</fpage><lpage>4393</lpage><pub-id pub-id-type="pmid">28424239</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1600714</pub-id><pub-id pub-id-type="pmcid">PMC5439025</pub-id></element-citation></ref><ref id="bib0265"><label>53</label><element-citation publication-type="journal" id="sbref0265"><person-group person-group-type="author"><name name-style="western"><surname>Oliveira</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Canetti</surname><given-names>C.</given-names></name><name name-style="western"><surname>Ribeiro</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Cunha</surname><given-names>F.Q.</given-names></name></person-group><article-title>Neutrophil migration induced by IL-1beta depends upon LTB4 released by macrophages and upon TNF-alpha and IL-1beta released by mast cells</article-title><source>Inflammation</source><volume>31</volume><year>2008</year><fpage>36</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">17874178</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1007/s10753-007-9047-x</pub-id></element-citation></ref><ref id="bib0270"><label>54</label><element-citation publication-type="journal" id="sbref0270"><person-group person-group-type="author"><name name-style="western"><surname>Prince</surname><given-names>L.R.</given-names></name><name name-style="western"><surname>Allen</surname><given-names>L.</given-names></name><name name-style="western"><surname>Jones</surname><given-names>E.C.</given-names></name><name name-style="western"><surname>Hellewell</surname><given-names>P.G.</given-names></name><name name-style="western"><surname>Dower</surname><given-names>S.K.</given-names></name><name name-style="western"><surname>Whyte</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Sabroe</surname><given-names>I.</given-names></name></person-group><article-title>The role of interleukin-1beta in direct and toll-like receptor 4-mediated neutrophil activation and survival</article-title><source>Am J Pathol</source><volume>165</volume><year>2004</year><fpage>1819</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">15509550</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/s0002-9440(10)63437-2</pub-id><pub-id pub-id-type="pmcid">PMC1618681</pub-id></element-citation></ref><ref id="bib0275"><label>55</label><element-citation publication-type="journal" id="sbref0275"><person-group person-group-type="author"><name name-style="western"><surname>Jorgensen</surname><given-names>I.</given-names></name><name name-style="western"><surname>Lopez</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Laufer</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>E.A.</given-names></name></person-group><article-title>IL-1beta, IL-18, and eicosanoids promote neutrophil recruitment to pore-induced intracellular traps following pyroptosis</article-title><source>Eur J Immunol</source><volume>46</volume><year>2016</year><fpage>2761</fpage><lpage>2766</lpage><pub-id pub-id-type="pmid">27682622</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.201646647</pub-id><pub-id pub-id-type="pmcid">PMC5138142</pub-id></element-citation></ref><ref id="bib0280"><label>56</label><element-citation publication-type="journal" id="sbref0280"><person-group person-group-type="author"><name name-style="western"><surname>Schenk</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fabri</surname><given-names>M.</given-names></name><name name-style="western"><surname>Krutzik</surname><given-names>S.R.</given-names></name><name name-style="western"><surname>Lee</surname><given-names>D.J.</given-names></name><name name-style="western"><surname>Vu</surname><given-names>D.M.</given-names></name><name name-style="western"><surname>Sieling</surname><given-names>P.A.</given-names></name><name name-style="western"><surname>Montoya</surname><given-names>D.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>P.T.</given-names></name><name name-style="western"><surname>Modlin</surname><given-names>R.L.</given-names></name></person-group><article-title>Interleukin-1beta triggers the differentiation of macrophages with enhanced capacity to present mycobacterial antigen to T cells</article-title><source>Immunology</source><volume>141</volume><year>2014</year><fpage>174</fpage><lpage>180</lpage><pub-id pub-id-type="pmid">24032597</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/imm.12167</pub-id><pub-id pub-id-type="pmcid">PMC3904238</pub-id></element-citation></ref><ref id="bib0285"><label>57</label><element-citation publication-type="journal" id="sbref0285"><person-group person-group-type="author"><name name-style="western"><surname>Yaqinuddin</surname><given-names>A.</given-names></name><name name-style="western"><surname>Kvietys</surname><given-names>P.</given-names></name><name name-style="western"><surname>Kashir</surname><given-names>J.</given-names></name></person-group><article-title>COVID-19: Role of neutrophil extracellular traps in acute lung injury</article-title><source>Respir Investig</source><volume>58</volume><year>2020</year><fpage>419</fpage><lpage>420</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.resinv.2020.06.001</pub-id><pub-id pub-id-type="pmcid">PMC7318928</pub-id><pub-id pub-id-type="pmid">32611518</pub-id></element-citation></ref><ref id="bib0290"><label>58</label><element-citation publication-type="journal" id="sbref0290"><person-group person-group-type="author"><name name-style="western"><surname>Kong</surname><given-names>M.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Mao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Z.</given-names></name></person-group><article-title>Higher level of neutrophil-to-lymphocyte is associated with severe COVID-19</article-title><source>Epidemiol Infect</source><volume>148</volume><year>2020</year><object-id pub-id-type="publisher-id">e139</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1017/S0950268820001557</pub-id><pub-id pub-id-type="pmcid">PMC7360950</pub-id><pub-id pub-id-type="pmid">32641174</pub-id></element-citation></ref><ref id="bib0295"><label>59&#8226;&#8226;</label><element-citation publication-type="journal" id="sbref0295"><person-group person-group-type="author"><name name-style="western"><surname>Veras</surname><given-names>F.P.</given-names></name><name name-style="western"><surname>Pontelli</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Silva</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Toller-Kawahisa</surname><given-names>J.E.</given-names></name><name name-style="western"><surname>de Lima</surname><given-names>M.</given-names></name><name name-style="western"><surname>Nascimento</surname><given-names>D.C.</given-names></name><name name-style="western"><surname>Schneider</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Caetite</surname><given-names>D.</given-names></name><name name-style="western"><surname>Tavares</surname><given-names>L.A.</given-names></name><name name-style="western"><surname>Paiva</surname><given-names>I.M.</given-names></name><etal/></person-group><article-title>SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology</article-title><source>J Exp Med</source><volume>217</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20201129</pub-id><pub-id pub-id-type="pmcid">PMC7488868</pub-id><pub-id pub-id-type="pmid">32926098</pub-id></element-citation><note><p>Neutrophil extracellular traps or NETs involve the release of nuclear DNA from neutrophils as a last line of defense to contain extracellular microbes. This process is highly inflammatory in nature and can promote further tissue damage. In this study, Veras&#160;<italic toggle="yes">et al.</italic> identify heightened levels of NETs in the plasma and tracheal aspirates of patients with COVID-19 compared to healthy controls. Heightened NETs were confirmed in lung tissue taken from autopsies of COVID-19 patients. They also show that SARS-CoV-2 virus can directly induce NET formation in healthy neutrophils and that these NETs promoted cell death of lung epithelial cells.</p></note></ref><ref id="bib0300"><label>60</label><element-citation publication-type="journal" id="sbref0300"><person-group person-group-type="author"><name name-style="western"><surname>Middleton</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>He</surname><given-names>X.Y.</given-names></name><name name-style="western"><surname>Denorme</surname><given-names>F.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>R.A.</given-names></name><name name-style="western"><surname>Ng</surname><given-names>D.</given-names></name><name name-style="western"><surname>Salvatore</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Mostyka</surname><given-names>M.</given-names></name><name name-style="western"><surname>Baxter-Stoltzfus</surname><given-names>A.</given-names></name><name name-style="western"><surname>Borczuk</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Loda</surname><given-names>M.</given-names></name><etal/></person-group><article-title>Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome</article-title><source>Blood</source><volume>136</volume><year>2020</year><fpage>1169</fpage><lpage>1179</lpage><pub-id pub-id-type="pmid">32597954</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1182/blood.2020007008</pub-id><pub-id pub-id-type="pmcid">PMC7472714</pub-id></element-citation></ref><ref id="bib0305"><label>61</label><element-citation publication-type="journal" id="sbref0305"><person-group person-group-type="author"><name name-style="western"><surname>Gomez-Rial</surname><given-names>J.</given-names></name><name name-style="western"><surname>Rivero-Calle</surname><given-names>I.</given-names></name><name name-style="western"><surname>Salas</surname><given-names>A.</given-names></name><name name-style="western"><surname>Martinon-Torres</surname><given-names>F.</given-names></name></person-group><article-title>Role of monocytes/macrophages in Covid-19 pathogenesis: implications for therapy</article-title><source>Infect Drug Resist</source><volume>13</volume><year>2020</year><fpage>2485</fpage><lpage>2493</lpage><pub-id pub-id-type="pmid">32801787</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.2147/IDR.S258639</pub-id><pub-id pub-id-type="pmcid">PMC7383015</pub-id></element-citation></ref><ref id="bib0310"><label>62</label><element-citation publication-type="journal" id="sbref0310"><person-group person-group-type="author"><name name-style="western"><surname>Otsuka</surname><given-names>R.</given-names></name><name name-style="western"><surname>Seino</surname><given-names>K.I.</given-names></name></person-group><article-title>Macrophage activation syndrome and COVID-19</article-title><source>Inflamm Regen</source><volume>40</volume><year>2020</year><object-id pub-id-type="publisher-id">19</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s41232-020-00131-w</pub-id><pub-id pub-id-type="pmcid">PMC7406680</pub-id><pub-id pub-id-type="pmid">32834892</pub-id></element-citation></ref><ref id="bib0315"><label>63&#8226;</label><element-citation publication-type="journal" id="sbref0315"><person-group person-group-type="author"><name name-style="western"><surname>Rodrigues</surname><given-names>T.S.</given-names></name><name name-style="western"><surname>de Sa</surname><given-names>K.S.G.</given-names></name><name name-style="western"><surname>Ishimoto</surname><given-names>A.Y.</given-names></name><name name-style="western"><surname>Becerra</surname><given-names>A.</given-names></name><name name-style="western"><surname>Oliveira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Almeida</surname><given-names>L.</given-names></name><name name-style="western"><surname>Goncalves</surname><given-names>A.V.</given-names></name><name name-style="western"><surname>Perucello</surname><given-names>D.B.</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>W.A.</given-names></name><name name-style="western"><surname>Castro</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients</article-title><source>J Exp Med</source><volume>218</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20201707</pub-id><pub-id pub-id-type="pmcid">PMC7684031</pub-id><pub-id pub-id-type="pmid">33231615</pub-id></element-citation><note><p>Rodrigues&#160;<italic toggle="yes">et al.</italic> demonstrate that SARS-CoV-2 virus can directly activate the NLRP3 inflammasome <italic toggle="yes">in vitro</italic> in primary human monocytes. Further, they find evidence of activated inflammasomes in the PBMCs of COVID-19 patients. Heightened active caspase-1 and IL-1&#946; were observed in COVID-19 patients and these measures correlated with disease severity. They confirmed their findings in lung autopsy tissue where they can also detect activated inflammasomes.</p></note></ref><ref id="bib0320"><label>64</label><element-citation publication-type="journal" id="sbref0320"><person-group person-group-type="author"><name name-style="western"><surname>Theobald</surname><given-names>S.J.</given-names></name><name name-style="western"><surname>Simonis</surname><given-names>A.</given-names></name><name name-style="western"><surname>Georgomanolis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Kreer</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zehner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Eisfeld</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Albert</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Chhen</surname><given-names>J.</given-names></name><name name-style="western"><surname>Motameny</surname><given-names>S.</given-names></name><name name-style="western"><surname>Erger</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19</article-title><source>EMBO Mol Med</source><volume>13</volume><year>2021</year><object-id pub-id-type="publisher-id">e14150</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.15252/emmm.202114150</pub-id><pub-id pub-id-type="pmcid">PMC8350892</pub-id><pub-id pub-id-type="pmid">34133077</pub-id></element-citation></ref><ref id="bib0325"><label>65</label><element-citation publication-type="journal" id="sbref0325"><person-group person-group-type="author"><name name-style="western"><surname>Shi</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>K.</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Zhuang</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Cai</surname><given-names>T.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><name name-style="western"><surname>Shao</surname><given-names>F.</given-names></name></person-group><article-title>Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death</article-title><source>Nature</source><volume>526</volume><year>2015</year><fpage>660</fpage><lpage>665</lpage><pub-id pub-id-type="pmid">26375003</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature15514</pub-id></element-citation></ref><ref id="bib0330"><label>66</label><element-citation publication-type="journal" id="sbref0330"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>X.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Ruan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Pan</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Magupalli</surname><given-names>V.G.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H.</given-names></name><name name-style="western"><surname>Lieberman</surname><given-names>J.</given-names></name></person-group><article-title>Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores</article-title><source>Nature</source><volume>535</volume><year>2016</year><fpage>153</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">27383986</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature18629</pub-id><pub-id pub-id-type="pmcid">PMC5539988</pub-id></element-citation></ref><ref id="bib0335"><label>67</label><element-citation publication-type="journal" id="sbref0335"><person-group person-group-type="author"><name name-style="western"><surname>Poggiali</surname><given-names>E.</given-names></name><name name-style="western"><surname>Zaino</surname><given-names>D.</given-names></name><name name-style="western"><surname>Immovilli</surname><given-names>P.</given-names></name><name name-style="western"><surname>Rovero</surname><given-names>L.</given-names></name><name name-style="western"><surname>Losi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Dacrema</surname><given-names>A.</given-names></name><name name-style="western"><surname>Nuccetelli</surname><given-names>M.</given-names></name><name name-style="western"><surname>Vadacca</surname><given-names>G.B.</given-names></name><name name-style="western"><surname>Guidetti</surname><given-names>D.</given-names></name><name name-style="western"><surname>Vercelli</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients</article-title><source>Clin Chim Acta</source><volume>509</volume><year>2020</year><fpage>135</fpage><lpage>138</lpage><pub-id pub-id-type="pmid">32531257</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2020.06.012</pub-id><pub-id pub-id-type="pmcid">PMC7282743</pub-id></element-citation></ref><ref id="bib0340"><label>68&#8226;</label><element-citation publication-type="journal" id="sbref0340"><person-group person-group-type="author"><name name-style="western"><surname>Henry</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Aggarwal</surname><given-names>G.</given-names></name><name name-style="western"><surname>Wong</surname><given-names>J.</given-names></name><name name-style="western"><surname>Benoit</surname><given-names>S.</given-names></name><name name-style="western"><surname>Vikse</surname><given-names>J.</given-names></name><name name-style="western"><surname>Plebani</surname><given-names>M.</given-names></name><name name-style="western"><surname>Lippi</surname><given-names>G.</given-names></name></person-group><article-title>Lactate dehydrogenase levels predict coronavirus disease 2019 (COVID-19) severity and mortality: a pooled analysis</article-title><source>Am J Emerg Med</source><volume>38</volume><year>2020</year><fpage>1722</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">32738466</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ajem.2020.05.073</pub-id><pub-id pub-id-type="pmcid">PMC7251362</pub-id></element-citation><note><p>This study, and others like it, were critical in establishing that specific forms of inflammation are associated with severe COVID-19 disease. LDH is released from necrotic and pyroptotic cells, showing that severe COVID-19 disease is associated with inflammatory lytic cell death. This represented some of the earliest evidence directly implicating the inflammasome and IL-1 in SARS-CoV-12 infection.</p></note></ref><ref id="bib0345"><label>69</label><element-citation publication-type="journal" id="sbref0345"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Mu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>W.</given-names></name><name name-style="western"><surname>Jin</surname><given-names>C.</given-names></name><name name-style="western"><surname>Tong</surname><given-names>C.</given-names></name><name name-style="western"><surname>Song</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Zha</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xue</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gu</surname><given-names>G.</given-names></name></person-group><article-title>Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study</article-title><source>Aging (Albany NY)</source><volume>12</volume><year>2020</year><fpage>11245</fpage><lpage>11258</lpage><pub-id pub-id-type="pmid">32633729</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.18632/aging.103372</pub-id><pub-id pub-id-type="pmcid">PMC7343511</pub-id></element-citation></ref><ref id="bib0350"><label>70</label><element-citation publication-type="journal" id="sbref0350"><person-group person-group-type="author"><name name-style="western"><surname>Huang</surname><given-names>I.</given-names></name><name name-style="western"><surname>Pranata</surname><given-names>R.</given-names></name></person-group><article-title>Lymphopenia in severe coronavirus disease-2019 (COVID-19): systematic review and meta-analysis</article-title><source>J Intensive Care</source><volume>8</volume><year>2020</year><object-id pub-id-type="publisher-id">36</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1186/s40560-020-00453-4</pub-id><pub-id pub-id-type="pmcid">PMC7245646</pub-id><pub-id pub-id-type="pmid">32483488</pub-id></element-citation></ref><ref id="bib0355"><label>71</label><element-citation publication-type="journal" id="sbref0355"><person-group person-group-type="author"><name name-style="western"><surname>Zhao</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Meng</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kumar</surname><given-names>R.</given-names></name><name name-style="western"><surname>Wu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Deng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Weng</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>L.</given-names></name></person-group><article-title>Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a systemic review and meta-analysis</article-title><source>Int J Infect Dis</source><volume>96</volume><year>2020</year><fpage>131</fpage><lpage>135</lpage><pub-id pub-id-type="pmid">32376308</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.ijid.2020.04.086</pub-id><pub-id pub-id-type="pmcid">PMC7196544</pub-id></element-citation></ref><ref id="bib0360"><label>72</label><element-citation publication-type="journal" id="sbref0360"><person-group person-group-type="author"><name name-style="western"><surname>Tan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Ding</surname><given-names>J.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Tang</surname><given-names>Y.Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Miao</surname><given-names>H.</given-names></name></person-group><article-title>Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study</article-title><source>Signal Transduct Target Ther</source><volume>5</volume><year>2020</year><object-id pub-id-type="publisher-id">33</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41392-020-0148-4</pub-id><pub-id pub-id-type="pmcid">PMC7100419</pub-id><pub-id pub-id-type="pmid">32296069</pub-id></element-citation></ref><ref id="bib0365"><label>73</label><element-citation publication-type="journal" id="sbref0365"><person-group person-group-type="author"><name name-style="western"><surname>Ridker</surname><given-names>P.M.</given-names></name></person-group><article-title>From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection</article-title><source>Circ Res</source><volume>118</volume><year>2016</year><fpage>145</fpage><lpage>156</lpage><pub-id pub-id-type="pmid">26837745</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1161/CIRCRESAHA.115.306656</pub-id><pub-id pub-id-type="pmcid">PMC4793711</pub-id></element-citation></ref><ref id="bib0370"><label>74</label><element-citation publication-type="journal" id="sbref0370"><person-group person-group-type="author"><name name-style="western"><surname>Cahill</surname><given-names>C.M.</given-names></name><name name-style="western"><surname>Rogers</surname><given-names>J.T.</given-names></name></person-group><article-title>Interleukin (IL) 1beta induction of IL-6 is mediated by a novel phosphatidylinositol 3-kinase-dependent AKT/IkappaB kinase alpha pathway targeting activator protein-1</article-title><source>J Biol Chem</source><volume>283</volume><year>2008</year><fpage>25900</fpage><lpage>25912</lpage><pub-id pub-id-type="pmid">18515365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1074/jbc.M707692200</pub-id><pub-id pub-id-type="pmcid">PMC2533786</pub-id></element-citation></ref><ref id="bib0375"><label>75</label><element-citation publication-type="journal" id="sbref0375"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>D.</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>S.L.</given-names></name><name name-style="western"><surname>Rzewnicki</surname><given-names>D.</given-names></name><name name-style="western"><surname>Samols</surname><given-names>D.</given-names></name><name name-style="western"><surname>Kushner</surname><given-names>I.</given-names></name></person-group><article-title>The effect of interleukin-1 on C-reactive protein expression in Hep3B cells is exerted at the transcriptional level</article-title><source>Biochem J</source><volume>310</volume><year>1995</year><fpage>143</fpage><lpage>148</lpage><pub-id pub-id-type="pmid">7646436</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1042/bj3100143</pub-id><pub-id pub-id-type="pmcid">PMC1135865</pub-id></element-citation></ref><ref id="bib0380"><label>76</label><element-citation publication-type="journal" id="sbref0380"><person-group person-group-type="author"><name name-style="western"><surname>Grifoni</surname><given-names>E.</given-names></name><name name-style="western"><surname>Valoriani</surname><given-names>A.</given-names></name><name name-style="western"><surname>Cei</surname><given-names>F.</given-names></name><name name-style="western"><surname>Lamanna</surname><given-names>R.</given-names></name><name name-style="western"><surname>Gelli</surname><given-names>A.M.G.</given-names></name><name name-style="western"><surname>Ciambotti</surname><given-names>B.</given-names></name><name name-style="western"><surname>Vannucchi</surname><given-names>V.</given-names></name><name name-style="western"><surname>Moroni</surname><given-names>F.</given-names></name><name name-style="western"><surname>Pelagatti</surname><given-names>L.</given-names></name><name name-style="western"><surname>Tarquini</surname><given-names>R.</given-names></name><etal/></person-group><article-title>Interleukin-6 as prognosticator in patients with COVID-19</article-title><source>J Infect</source><volume>81</volume><year>2020</year><fpage>452</fpage><lpage>482</lpage><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jinf.2020.06.008</pub-id><pub-id pub-id-type="pmcid">PMC7278637</pub-id><pub-id pub-id-type="pmid">32526326</pub-id></element-citation></ref><ref id="bib0385"><label>77</label><element-citation publication-type="journal" id="sbref0385"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>N.</given-names></name></person-group><article-title>Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19</article-title><source>J Med Virol</source><volume>92</volume><year>2020</year><fpage>2409</fpage><lpage>2411</lpage><pub-id pub-id-type="pmid">32516845</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/jmv.26097</pub-id><pub-id pub-id-type="pmcid">PMC7301027</pub-id></element-citation></ref><ref id="bib0390"><label>78</label><element-citation publication-type="journal" id="sbref0390"><person-group person-group-type="author"><name name-style="western"><surname>Sahu</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Kampa</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Padhi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Panda</surname><given-names>A.K.</given-names></name></person-group><article-title>C-reactive protein: a promising biomarker for poor prognosis in COVID-19 infection</article-title><source>Clin Chim Acta</source><volume>509</volume><year>2020</year><fpage>91</fpage><lpage>94</lpage><pub-id pub-id-type="pmid">32511972</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cca.2020.06.013</pub-id><pub-id pub-id-type="pmcid">PMC7274122</pub-id></element-citation></ref><ref id="bib0395"><label>79</label><element-citation publication-type="journal" id="sbref0395"><person-group person-group-type="author"><name name-style="western"><surname>Gubernatorova</surname><given-names>E.O.</given-names></name><name name-style="western"><surname>Gorshkova</surname><given-names>E.A.</given-names></name><name name-style="western"><surname>Polinova</surname><given-names>A.I.</given-names></name><name name-style="western"><surname>Drutskaya</surname><given-names>M.S.</given-names></name></person-group><article-title>IL-6: relevance for immunopathology of SARS-CoV-2</article-title><source>Cytokine Growth Factor Rev</source><volume>53</volume><year>2020</year><fpage>13</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">32475759</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cytogfr.2020.05.009</pub-id><pub-id pub-id-type="pmcid">PMC7237916</pub-id></element-citation></ref><ref id="bib0400"><label>80</label><element-citation publication-type="journal" id="sbref0400"><person-group person-group-type="author"><name name-style="western"><surname>Ferreira</surname><given-names>A.C.</given-names></name><name name-style="western"><surname>Soares</surname><given-names>V.C.</given-names></name><name name-style="western"><surname>de Azevedo-Quintanilha</surname><given-names>I.G.</given-names></name><name name-style="western"><surname>Dias</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fintelman-Rodrigues</surname><given-names>N.</given-names></name><name name-style="western"><surname>Sacramento</surname><given-names>C.Q.</given-names></name><name name-style="western"><surname>Mattos</surname><given-names>M.</given-names></name><name name-style="western"><surname>de Freitas</surname><given-names>C.S.</given-names></name><name name-style="western"><surname>Temerozo</surname><given-names>J.R.</given-names></name><name name-style="western"><surname>Teixeira</surname><given-names>L.</given-names></name><etal/></person-group><article-title>SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes</article-title><source>Cell Death Discov</source><volume>7</volume><year>2021</year><object-id pub-id-type="publisher-id">43</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41420-021-00428-w</pub-id><pub-id pub-id-type="pmcid">PMC7919254</pub-id><pub-id pub-id-type="pmid">33649297</pub-id></element-citation></ref><ref id="bib0405"><label>81&#8226;&#8226;</label><element-citation publication-type="journal" id="sbref0405"><person-group person-group-type="author"><name name-style="western"><surname>Liao</surname><given-names>M.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wen</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>G.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>L.</given-names></name><name name-style="western"><surname>Li</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>X.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F.</given-names></name><etal/></person-group><article-title>Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19</article-title><source>Nat Med</source><volume>26</volume><year>2020</year><fpage>842</fpage><lpage>844</lpage><pub-id pub-id-type="pmid">32398875</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-020-0901-9</pub-id></element-citation><note><p>In one of the first OMICs datasets to be generated during the SARS-CoV-2 pandemic, Liao&#160;<italic toggle="yes">et al.</italic> used single cell sequencing of the bronchoalveloar lavage fluid to identify infiltration innate immune cells including monocytes/macrophages and neutrophils as a feature of severe disease. This provided some of the first direct experimental evidence that infiltrating inflammatory innate immune cells were a key mediator of disease pathology.</p></note></ref><ref id="bib0410"><label>82</label><element-citation publication-type="journal" id="sbref0410"><person-group person-group-type="author"><name name-style="western"><surname>Gyawali</surname><given-names>B.</given-names></name><name name-style="western"><surname>Ramakrishna</surname><given-names>K.</given-names></name><name name-style="western"><surname>Dhamoon</surname><given-names>A.S.</given-names></name></person-group><article-title>Sepsis: the evolution in definition, pathophysiology, and management</article-title><source>SAGE Open Med</source><volume>7</volume><year>2019</year><object-id pub-id-type="publisher-id">2050312119835043</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1177/2050312119835043</pub-id><pub-id pub-id-type="pmcid">PMC6429642</pub-id><pub-id pub-id-type="pmid">30915218</pub-id></element-citation></ref><ref id="bib0415"><label>83</label><element-citation publication-type="journal" id="sbref0415"><person-group person-group-type="author"><name name-style="western"><surname>Seydoux</surname><given-names>E.</given-names></name><name name-style="western"><surname>Liang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Dubois Cauwelaert</surname><given-names>N.</given-names></name><name name-style="western"><surname>Archer</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rintala</surname><given-names>N.D.</given-names></name><name name-style="western"><surname>Kramer</surname><given-names>R.</given-names></name><name name-style="western"><surname>Carter</surname><given-names>D.</given-names></name><name name-style="western"><surname>Fox</surname><given-names>C.B.</given-names></name><name name-style="western"><surname>Orr</surname><given-names>M.T.</given-names></name></person-group><article-title>Effective combination adjuvants engage both TLR and inflammasome pathways to promote potent adaptive immune responses</article-title><source>J Immunol</source><volume>201</volume><year>2018</year><fpage>98</fpage><lpage>112</lpage><pub-id pub-id-type="pmid">29769270</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1701604</pub-id><pub-id pub-id-type="pmcid">PMC6008227</pub-id></element-citation></ref><ref id="bib0420"><label>84</label><element-citation publication-type="journal" id="sbref0420"><person-group person-group-type="author"><name name-style="western"><surname>Barbet</surname><given-names>G.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Geswell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Leonardi</surname><given-names>I.</given-names></name><name name-style="western"><surname>Cerutti</surname><given-names>A.</given-names></name><name name-style="western"><surname>Iliev</surname><given-names>I.</given-names></name><name name-style="western"><surname>Blander</surname><given-names>J.M.</given-names></name></person-group><article-title>Sensing microbial viability through bacterial RNA augments T follicular helper cell and antibody responses</article-title><source>Immunity</source><volume>48</volume><year>2018</year><fpage>584</fpage><lpage>598.e5</lpage><pub-id pub-id-type="pmid">29548673</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2018.02.015</pub-id><pub-id pub-id-type="pmcid">PMC5924674</pub-id></element-citation></ref><ref id="bib0425"><label>85</label><element-citation publication-type="journal" id="sbref0425"><person-group person-group-type="author"><name name-style="western"><surname>Gaucher</surname><given-names>D.</given-names></name><name name-style="western"><surname>Therrien</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kettaf</surname><given-names>N.</given-names></name><name name-style="western"><surname>Angermann</surname><given-names>B.R.</given-names></name><name name-style="western"><surname>Boucher</surname><given-names>G.</given-names></name><name name-style="western"><surname>Filali-Mouhim</surname><given-names>A.</given-names></name><name name-style="western"><surname>Moser</surname><given-names>J.M.</given-names></name><name name-style="western"><surname>Mehta</surname><given-names>R.S.</given-names></name><name name-style="western"><surname>Drake</surname><given-names>D.R.</given-names><suffix>3rd</suffix></name><name name-style="western"><surname>Castro</surname><given-names>E.</given-names></name><etal/></person-group><article-title>Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses</article-title><source>J Exp Med</source><volume>205</volume><year>2008</year><fpage>3119</fpage><lpage>3131</lpage><pub-id pub-id-type="pmid">19047440</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1084/jem.20082292</pub-id><pub-id pub-id-type="pmcid">PMC2605227</pub-id></element-citation></ref><ref id="bib0430"><label>86</label><element-citation publication-type="journal" id="sbref0430"><person-group person-group-type="author"><name name-style="western"><surname>Deng</surname><given-names>J.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>X.Q.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>P.H.</given-names></name></person-group><article-title>Inflammasome activation and Th17 responses</article-title><source>Mol Immunol</source><volume>107</volume><year>2019</year><fpage>142</fpage><lpage>164</lpage><pub-id pub-id-type="pmid">30739833</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.molimm.2018.12.024</pub-id></element-citation></ref><ref id="bib0435"><label>87</label><element-citation publication-type="journal" id="sbref0435"><person-group person-group-type="author"><name name-style="western"><surname>Harrison</surname><given-names>O.J.</given-names></name><name name-style="western"><surname>Srinivasan</surname><given-names>N.</given-names></name><name name-style="western"><surname>Pott</surname><given-names>J.</given-names></name><name name-style="western"><surname>Schiering</surname><given-names>C.</given-names></name><name name-style="western"><surname>Krausgruber</surname><given-names>T.</given-names></name><name name-style="western"><surname>Ilott</surname><given-names>N.E.</given-names></name><name name-style="western"><surname>Maloy</surname><given-names>K.J.</given-names></name></person-group><article-title>Epithelial-derived IL-18 regulates Th17 cell differentiation and Foxp3(+) Treg cell function in the intestine</article-title><source>Mucosal Immunol</source><volume>8</volume><year>2015</year><fpage>1226</fpage><lpage>1236</lpage><pub-id pub-id-type="pmid">25736457</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/mi.2015.13</pub-id><pub-id pub-id-type="pmcid">PMC4368110</pub-id></element-citation></ref><ref id="bib0440"><label>88</label><element-citation publication-type="journal" id="sbref0440"><person-group person-group-type="author"><name name-style="western"><surname>Chung</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Martinez</surname><given-names>G.J.</given-names></name><name name-style="western"><surname>Yang</surname><given-names>X.O.</given-names></name><name name-style="western"><surname>Nurieva</surname><given-names>R.</given-names></name><name name-style="western"><surname>Kang</surname><given-names>H.S.</given-names></name><name name-style="western"><surname>Ma</surname><given-names>L.</given-names></name><name name-style="western"><surname>Watowich</surname><given-names>S.S.</given-names></name><name name-style="western"><surname>Jetten</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Tian</surname><given-names>Q.</given-names></name><etal/></person-group><article-title>Critical regulation of early Th17 cell differentiation by interleukin-1 signaling</article-title><source>Immunity</source><volume>30</volume><year>2009</year><fpage>576</fpage><lpage>587</lpage><pub-id pub-id-type="pmid">19362022</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.immuni.2009.02.007</pub-id><pub-id pub-id-type="pmcid">PMC2705871</pub-id></element-citation></ref><ref id="bib0445"><label>89</label><element-citation publication-type="journal" id="sbref0445"><person-group person-group-type="author"><name name-style="western"><surname>Kupz</surname><given-names>A.</given-names></name><name name-style="western"><surname>Guarda</surname><given-names>G.</given-names></name><name name-style="western"><surname>Gebhardt</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sander</surname><given-names>L.E.</given-names></name><name name-style="western"><surname>Short</surname><given-names>K.R.</given-names></name><name name-style="western"><surname>Diavatopoulos</surname><given-names>D.A.</given-names></name><name name-style="western"><surname>Wijburg</surname><given-names>O.L.</given-names></name><name name-style="western"><surname>Cao</surname><given-names>H.</given-names></name><name name-style="western"><surname>Waithman</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W.</given-names></name><etal/></person-group><article-title>NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8(+) T cells</article-title><source>Nat Immunol</source><volume>13</volume><year>2012</year><fpage>162</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">22231517</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/ni.2195</pub-id></element-citation></ref><ref id="bib0450"><label>90</label><element-citation publication-type="journal" id="sbref0450"><person-group person-group-type="author"><name name-style="western"><surname>Eisenbarth</surname><given-names>S.C.</given-names></name><name name-style="western"><surname>Colegio</surname><given-names>O.R.</given-names></name><name name-style="western"><surname>O&#8217;Connor</surname><given-names>W.</given-names></name><name name-style="western"><surname>Sutterwala</surname><given-names>F.S.</given-names></name><name name-style="western"><surname>Flavell</surname><given-names>R.A.</given-names></name></person-group><article-title>Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants</article-title><source>Nature</source><volume>453</volume><year>2008</year><fpage>1122</fpage><lpage>1126</lpage><pub-id pub-id-type="pmid">18496530</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/nature06939</pub-id><pub-id pub-id-type="pmcid">PMC4804622</pub-id></element-citation></ref><ref id="bib0455"><label>91</label><element-citation publication-type="journal" id="sbref0455"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H.</given-names></name><name name-style="western"><surname>Willingham</surname><given-names>S.B.</given-names></name><name name-style="western"><surname>Ting</surname><given-names>J.P.</given-names></name><name name-style="western"><surname>Re</surname><given-names>F.</given-names></name></person-group><article-title>Cutting edge: inflammasome activation by alum and alum&#8217;s adjuvant effect are mediated by NLRP3</article-title><source>J Immunol</source><volume>181</volume><year>2008</year><fpage>17</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">18566365</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.181.1.17</pub-id><pub-id pub-id-type="pmcid">PMC2587213</pub-id></element-citation></ref><ref id="bib0460"><label>92</label><element-citation publication-type="journal" id="sbref0460"><person-group person-group-type="author"><name name-style="western"><surname>Darweesh</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kamel</surname><given-names>W.</given-names></name><name name-style="western"><surname>Gavrilin</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Akusjarvi</surname><given-names>G.</given-names></name><name name-style="western"><surname>Svensson</surname><given-names>C.</given-names></name></person-group><article-title>Adenovirus VA RNAI blocks ASC oligomerization and inhibits NLRP3 inflammasome activation</article-title><source>Front Immunol</source><volume>10</volume><year>2019</year><object-id pub-id-type="publisher-id">2791</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02791</pub-id><pub-id pub-id-type="pmcid">PMC6901988</pub-id><pub-id pub-id-type="pmid">31849970</pub-id></element-citation></ref><ref id="bib0465"><label>93</label><element-citation publication-type="journal" id="sbref0465"><person-group person-group-type="author"><name name-style="western"><surname>Barlan</surname><given-names>A.U.</given-names></name><name name-style="western"><surname>Griffin</surname><given-names>T.M.</given-names></name><name name-style="western"><surname>McGuire</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Wiethoff</surname><given-names>C.M.</given-names></name></person-group><article-title>Adenovirus membrane penetration activates the NLRP3 inflammasome</article-title><source>J Virol</source><volume>85</volume><year>2011</year><fpage>146</fpage><lpage>155</lpage><pub-id pub-id-type="pmid">20980503</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1128/JVI.01265-10</pub-id><pub-id pub-id-type="pmcid">PMC3014182</pub-id></element-citation></ref><ref id="bib0470"><label>94</label><element-citation publication-type="journal" id="sbref0470"><person-group person-group-type="author"><name name-style="western"><surname>Suschak</surname><given-names>J.J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>S.</given-names></name><name name-style="western"><surname>Fitzgerald</surname><given-names>K.A.</given-names></name><name name-style="western"><surname>Lu</surname><given-names>S.</given-names></name></person-group><article-title>Identification of Aim2 as a sensor for DNA vaccines</article-title><source>J Immunol</source><volume>194</volume><year>2015</year><fpage>630</fpage><lpage>636</lpage><pub-id pub-id-type="pmid">25488991</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1402530</pub-id><pub-id pub-id-type="pmcid">PMC4282968</pub-id></element-citation></ref><ref id="bib0475"><label>95</label><element-citation publication-type="journal" id="sbref0475"><person-group person-group-type="author"><name name-style="western"><surname>Oleszycka</surname><given-names>E.</given-names></name><name name-style="western"><surname>Moran</surname><given-names>H.B.</given-names></name><name name-style="western"><surname>Tynan</surname><given-names>G.A.</given-names></name><name name-style="western"><surname>Hearnden</surname><given-names>C.H.</given-names></name><name name-style="western"><surname>Coutts</surname><given-names>G.</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>M.</given-names></name><name name-style="western"><surname>Allan</surname><given-names>S.M.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Lavelle</surname><given-names>E.C.</given-names></name></person-group><article-title>IL-1alpha and inflammasome-independent IL-1beta promote neutrophil infiltration following alum vaccination</article-title><source>FEBS J</source><volume>283</volume><year>2016</year><fpage>9</fpage><lpage>24</lpage><pub-id pub-id-type="pmid">26536497</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1111/febs.13546</pub-id></element-citation></ref><ref id="bib0480"><label>96</label><element-citation publication-type="journal" id="sbref0480"><person-group person-group-type="author"><name name-style="western"><surname>McKee</surname><given-names>A.S.</given-names></name><name name-style="western"><surname>Munks</surname><given-names>M.W.</given-names></name><name name-style="western"><surname>MacLeod</surname><given-names>M.K.</given-names></name><name name-style="western"><surname>Fleenor</surname><given-names>C.J.</given-names></name><name name-style="western"><surname>Van Rooijen</surname><given-names>N.</given-names></name><name name-style="western"><surname>Kappler</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Marrack</surname><given-names>P.</given-names></name></person-group><article-title>Alum induces innate immune responses through macrophage and mast cell sensors, but these sensors are not required for alum to act as an adjuvant for specific immunity</article-title><source>J Immunol</source><volume>183</volume><year>2009</year><fpage>4403</fpage><lpage>4414</lpage><pub-id pub-id-type="pmid">19734227</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.0900164</pub-id><pub-id pub-id-type="pmcid">PMC2912728</pub-id></element-citation></ref><ref id="bib0485"><label>97</label><element-citation publication-type="journal" id="sbref0485"><person-group person-group-type="author"><name name-style="western"><surname>Franchi</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nunez</surname><given-names>G.</given-names></name></person-group><article-title>The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1beta secretion but dispensable for adjuvant activity</article-title><source>Eur J Immunol</source><volume>38</volume><year>2008</year><fpage>2085</fpage><lpage>2089</lpage><pub-id pub-id-type="pmid">18624356</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.200838549</pub-id><pub-id pub-id-type="pmcid">PMC2759997</pub-id></element-citation></ref><ref id="bib0490"><label>98</label><element-citation publication-type="journal" id="sbref0490"><person-group person-group-type="author"><name name-style="western"><surname>Knudsen</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Kostic</surname><given-names>L.</given-names></name><name name-style="western"><surname>Nordstrom</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Tegerstedt</surname><given-names>K.</given-names></name><name name-style="western"><surname>Pasetto</surname><given-names>A.</given-names></name><name name-style="western"><surname>Applequist</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Ljungberg</surname><given-names>K.</given-names></name><name name-style="western"><surname>Sirard</surname><given-names>J.C.</given-names></name><name name-style="western"><surname>Liljestrom</surname><given-names>P.</given-names></name></person-group><article-title>The adjuvant activity of alphavirus replicons is enhanced by incorporating the microbial molecule flagellin into the replicon</article-title><source>PLoS One</source><volume>8</volume><year>2013</year><object-id pub-id-type="publisher-id">e65964</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1371/journal.pone.0065964</pub-id><pub-id pub-id-type="pmcid">PMC3681802</pub-id><pub-id pub-id-type="pmid">23785460</pub-id></element-citation></ref><ref id="bib0495"><label>99</label><element-citation publication-type="journal" id="sbref0495"><person-group person-group-type="author"><name name-style="western"><surname>Nystrom</surname><given-names>S.</given-names></name><name name-style="western"><surname>Brave</surname><given-names>A.</given-names></name><name name-style="western"><surname>Falkeborn</surname><given-names>T.</given-names></name><name name-style="western"><surname>Devito</surname><given-names>C.</given-names></name><name name-style="western"><surname>Rissiek</surname><given-names>B.</given-names></name><name name-style="western"><surname>Johansson</surname><given-names>D.X.</given-names></name><name name-style="western"><surname>Schroder</surname><given-names>U.</given-names></name><name name-style="western"><surname>Uematsu</surname><given-names>S.</given-names></name><name name-style="western"><surname>Akira</surname><given-names>S.</given-names></name><name name-style="western"><surname>Hinkula</surname><given-names>J.</given-names></name><etal/></person-group><article-title>DNA-encoded flagellin activates toll-like receptor 5 (TLR5), nod-like receptor family CARD domain-containing protein 4 (NRLC4), and acts as an epidermal, systemic, and mucosal-adjuvant</article-title><source>Vaccines (Basel)</source><volume>1</volume><year>2013</year><fpage>415</fpage><lpage>443</lpage><pub-id pub-id-type="pmid">26344341</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/vaccines1040415</pub-id><pub-id pub-id-type="pmcid">PMC4494208</pub-id></element-citation></ref><ref id="bib0500"><label>100</label><element-citation publication-type="journal" id="sbref0500"><person-group person-group-type="author"><name name-style="western"><surname>Lopez-Yglesias</surname><given-names>A.H.</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X.</given-names></name><name name-style="western"><surname>Quarles</surname><given-names>E.K.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>VandenBos</surname><given-names>T.</given-names></name><name name-style="western"><surname>Strong</surname><given-names>R.K.</given-names></name><name name-style="western"><surname>Smith</surname><given-names>K.D.</given-names></name></person-group><article-title>Flagellin induces antibody responses through a TLR5- and inflammasome-independent pathway</article-title><source>J Immunol</source><volume>192</volume><year>2014</year><fpage>1587</fpage><lpage>1596</lpage><pub-id pub-id-type="pmid">24442437</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1301893</pub-id><pub-id pub-id-type="pmcid">PMC3925749</pub-id></element-citation></ref><ref id="bib0505"><label>101</label><element-citation publication-type="journal" id="sbref0505"><person-group person-group-type="author"><name name-style="western"><surname>Vijay-Kumar</surname><given-names>M.</given-names></name><name name-style="western"><surname>Carvalho</surname><given-names>F.A.</given-names></name><name name-style="western"><surname>Aitken</surname><given-names>J.D.</given-names></name><name name-style="western"><surname>Fifadara</surname><given-names>N.H.</given-names></name><name name-style="western"><surname>Gewirtz</surname><given-names>A.T.</given-names></name></person-group><article-title>TLR5 or NLRC4 is necessary and sufficient for promotion of humoral immunity by flagellin</article-title><source>Eur J Immunol</source><volume>40</volume><year>2010</year><fpage>3528</fpage><lpage>3534</lpage><pub-id pub-id-type="pmid">21072873</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1002/eji.201040421</pub-id><pub-id pub-id-type="pmcid">PMC3081661</pub-id></element-citation></ref><ref id="bib0510"><label>102</label><element-citation publication-type="journal" id="sbref0510"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>van de Veerdonk</surname><given-names>F.L.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.</given-names></name><name name-style="western"><surname>Dinarello</surname><given-names>C.A.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.</given-names></name></person-group><article-title>Inflammasome-independent regulation of IL-1-family cytokines</article-title><source>Annu Rev Immunol</source><volume>33</volume><year>2015</year><fpage>49</fpage><lpage>77</lpage><pub-id pub-id-type="pmid">25493334</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1146/annurev-immunol-032414-112306</pub-id></element-citation></ref><ref id="bib0515"><label>103</label><element-citation publication-type="journal" id="sbref0515"><person-group person-group-type="author"><name name-style="western"><surname>Hagan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Cortese</surname><given-names>M.</given-names></name><name name-style="western"><surname>Rouphael</surname><given-names>N.</given-names></name><name name-style="western"><surname>Boudreau</surname><given-names>C.</given-names></name><name name-style="western"><surname>Linde</surname><given-names>C.</given-names></name><name name-style="western"><surname>Maddur</surname><given-names>M.S.</given-names></name><name name-style="western"><surname>Das</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H.</given-names></name><name name-style="western"><surname>Guthmiller</surname><given-names>J.</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>N.Y.</given-names></name><etal/></person-group><article-title>Antibiotics-driven gut microbiome perturbation alters immunity to vaccines in humans</article-title><source>Cell</source><volume>178</volume><year>2019</year><fpage>1313</fpage><lpage>1328.e3</lpage><pub-id pub-id-type="pmid">31491384</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2019.08.010</pub-id><pub-id pub-id-type="pmcid">PMC6750738</pub-id></element-citation></ref><ref id="bib0520"><label>104</label><element-citation publication-type="journal" id="sbref0520"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>F.</given-names></name><name name-style="western"><surname>Niu</surname><given-names>Q.</given-names></name><name name-style="western"><surname>Fan</surname><given-names>X.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>C.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></name><name name-style="western"><surname>Wei</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Hou</surname><given-names>W.</given-names></name><name name-style="western"><surname>Kanneganti</surname><given-names>T.D.</given-names></name><name name-style="western"><surname>Robb</surname><given-names>M.L.</given-names></name><name name-style="western"><surname>Kim</surname><given-names>J.H.</given-names></name><etal/></person-group><article-title>Priming and activation of inflammasome by canarypox virus vector ALVAC via the cGAS/IFI16-STING-Type I IFN pathway and AIM2 sensor</article-title><source>J Immunol</source><volume>199</volume><year>2017</year><fpage>3293</fpage><lpage>3305</lpage><pub-id pub-id-type="pmid">28947539</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.4049/jimmunol.1700698</pub-id><pub-id pub-id-type="pmcid">PMC5679316</pub-id></element-citation></ref><ref id="bib0525"><label>105</label><element-citation publication-type="journal" id="sbref0525"><person-group person-group-type="author"><name name-style="western"><surname>Vaccari</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fourati</surname><given-names>S.</given-names></name><name name-style="western"><surname>Gordon</surname><given-names>S.N.</given-names></name><name name-style="western"><surname>Brown</surname><given-names>D.R.</given-names></name><name name-style="western"><surname>Bissa</surname><given-names>M.</given-names></name><name name-style="western"><surname>Schifanella</surname><given-names>L.</given-names></name><name name-style="western"><surname>Silva de Castro</surname><given-names>I.</given-names></name><name name-style="western"><surname>Doster</surname><given-names>M.N.</given-names></name><name name-style="western"><surname>Galli</surname><given-names>V.</given-names></name><name name-style="western"><surname>Omsland</surname><given-names>M.</given-names></name><etal/></person-group><article-title>HIV vaccine candidate activation of hypoxia and the inflammasome in CD14(+) monocytes is associated with a decreased risk of SIVmac251 acquisition</article-title><source>Nat Med</source><volume>24</volume><year>2018</year><fpage>847</fpage><lpage>856</lpage><pub-id pub-id-type="pmid">29785023</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41591-018-0025-7</pub-id><pub-id pub-id-type="pmcid">PMC5992093</pub-id></element-citation></ref><ref id="bib0530"><label>106&#8226;&#8226;</label><element-citation publication-type="journal" id="sbref0530"><person-group person-group-type="author"><name name-style="western"><surname>Arunachalam</surname><given-names>P.S.</given-names></name><name name-style="western"><surname>Scott</surname><given-names>M.K.D.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>T.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Feng</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Wimmers</surname><given-names>F.</given-names></name><name name-style="western"><surname>Grigoryan</surname><given-names>L.</given-names></name><name name-style="western"><surname>Trisal</surname><given-names>M.</given-names></name><name name-style="western"><surname>Edara</surname><given-names>V.V.</given-names></name><name name-style="western"><surname>Lai</surname><given-names>L.</given-names></name><etal/></person-group><article-title>Systems vaccinology of the BNT162b2 mRNA vaccine in humans</article-title><source>Nature</source><volume>596</volume><year>2021</year><fpage>410</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">34252919</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41586-021-03791-x</pub-id><pub-id pub-id-type="pmcid">PMC8761119</pub-id></element-citation><note><p>This study is a critical source of information on the efficacious immune responses generated by the Pfizer vaccine. Using a Systems Immunology approach, the authors are able to interrogate the key aspects of immune function augmented by the vaccine, including polyfunction CD4 and CD8 T cells responses, innate immune signaling and heightened Ab titers.</p></note></ref><ref id="bib0535"><label>107&#8226;&#8226;</label><element-citation publication-type="journal" id="sbref0535"><person-group person-group-type="author"><name name-style="western"><surname>Wimmers</surname><given-names>F.</given-names></name><name name-style="western"><surname>Donato</surname><given-names>M.</given-names></name><name name-style="western"><surname>Kuo</surname><given-names>A.</given-names></name><name name-style="western"><surname>Ashuach</surname><given-names>T.</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S.</given-names></name><name name-style="western"><surname>Li</surname><given-names>C.</given-names></name><name name-style="western"><surname>Dvorak</surname><given-names>M.</given-names></name><name name-style="western"><surname>Foecke</surname><given-names>M.H.</given-names></name><name name-style="western"><surname>Chang</surname><given-names>S.E.</given-names></name><name name-style="western"><surname>Hagan</surname><given-names>T.</given-names></name><etal/></person-group><article-title>The single-cell epigenomic and transcriptional landscape of immunity to influenza vaccination</article-title><source>Cell</source><volume>184</volume><year>2021</year><fpage>3915</fpage><lpage>3935.e21</lpage><pub-id pub-id-type="pmid">34174187</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.cell.2021.05.039</pub-id><pub-id pub-id-type="pmcid">PMC8316438</pub-id></element-citation><note><p>In this paper, Wimmers&#160;<italic toggle="yes">et al.</italic> are able to demonstrate that influenza vaccination induces not only transcriptional changes but modulates the epigenetic landscape of the vaccine, conferring long-lived changes in chromatin accessibility which impact on future responses. Importantly, they show that months after vaccination these epigenetic modifications render cells refractory to infection by both homologous and heterologous viruses. This concept of vaccine induced trained antiviral immunity represents a major mechanism that can be leveraged in vaccines, including SARS-CoV-2, to promote better efficacy and prevent future infections.</p></note></ref><ref id="bib0540"><label>108</label><element-citation publication-type="journal" id="sbref0540"><person-group person-group-type="author"><name name-style="western"><surname>van der Heijden</surname><given-names>C.</given-names></name><name name-style="western"><surname>Noz</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.B.</given-names></name><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Riksen</surname><given-names>N.P.</given-names></name><name name-style="western"><surname>Keating</surname><given-names>S.T.</given-names></name></person-group><article-title>Epigenetics and trained immunity</article-title><source>Antioxid Redox Signal</source><volume>29</volume><year>2018</year><fpage>1023</fpage><lpage>1040</lpage><pub-id pub-id-type="pmid">28978221</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1089/ars.2017.7310</pub-id><pub-id pub-id-type="pmcid">PMC6121175</pub-id></element-citation></ref><ref id="bib0545"><label>109</label><element-citation publication-type="journal" id="sbref0545"><person-group person-group-type="author"><name name-style="western"><surname>Netea</surname><given-names>M.G.</given-names></name><name name-style="western"><surname>Dominguez-Andres</surname><given-names>J.</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Chavakis</surname><given-names>T.</given-names></name><name name-style="western"><surname>Divangahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Fuchs</surname><given-names>E.</given-names></name><name name-style="western"><surname>Joosten</surname><given-names>L.A.B.</given-names></name><name name-style="western"><surname>van der Meer</surname><given-names>J.W.M.</given-names></name><name name-style="western"><surname>Mhlanga</surname><given-names>M.M.</given-names></name><name name-style="western"><surname>Mulder</surname><given-names>W.J.M.</given-names></name><etal/></person-group><article-title>Defining trained immunity and its role in health and disease</article-title><source>Nat Rev Immunol</source><volume>20</volume><year>2020</year><fpage>375</fpage><lpage>388</lpage><pub-id pub-id-type="pmid">32132681</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41577-020-0285-6</pub-id><pub-id pub-id-type="pmcid">PMC7186935</pub-id></element-citation></ref><ref id="bib0550"><label>110</label><element-citation publication-type="journal" id="sbref0550"><person-group person-group-type="author"><name name-style="western"><surname>Owen</surname><given-names>A.M.</given-names></name><name name-style="western"><surname>Fults</surname><given-names>J.B.</given-names></name><name name-style="western"><surname>Patil</surname><given-names>N.K.</given-names></name><name name-style="western"><surname>Hernandez</surname><given-names>A.</given-names></name><name name-style="western"><surname>Bohannon</surname><given-names>J.K.</given-names></name></person-group><article-title>TLR agonists as mediators of trained immunity: mechanistic insight and immunotherapeutic potential to combat infection</article-title><source>Front Immunol</source><volume>11</volume><year>2020</year><object-id pub-id-type="publisher-id">622614</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2020.622614</pub-id><pub-id pub-id-type="pmcid">PMC7930332</pub-id><pub-id pub-id-type="pmid">33679711</pub-id></element-citation></ref><ref id="bib0555"><label>111</label><element-citation publication-type="journal" id="sbref0555"><person-group person-group-type="author"><name name-style="western"><surname>Divangahi</surname><given-names>M.</given-names></name><name name-style="western"><surname>Aaby</surname><given-names>P.</given-names></name><name name-style="western"><surname>Khader</surname><given-names>S.A.</given-names></name><name name-style="western"><surname>Barreiro</surname><given-names>L.B.</given-names></name><name name-style="western"><surname>Bekkering</surname><given-names>S.</given-names></name><name name-style="western"><surname>Chavakis</surname><given-names>T.</given-names></name><name name-style="western"><surname>van Crevel</surname><given-names>R.</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N.</given-names></name><name name-style="western"><surname>DiNardo</surname><given-names>A.R.</given-names></name><name name-style="western"><surname>Dominguez-Andres</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Trained immunity, tolerance, priming and differentiation: distinct immunological processes</article-title><source>Nat Immunol</source><volume>22</volume><year>2021</year><fpage>2</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">33293712</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1038/s41590-020-00845-6</pub-id><pub-id pub-id-type="pmcid">PMC8020292</pub-id></element-citation></ref><ref id="bib0560"><label>112</label><element-citation publication-type="journal" id="sbref0560"><person-group person-group-type="author"><name name-style="western"><surname>Luchner</surname><given-names>M.</given-names></name><name name-style="western"><surname>Reinke</surname><given-names>S.</given-names></name><name name-style="western"><surname>Milicic</surname><given-names>A.</given-names></name></person-group><article-title>TLR agonists as vaccine adjuvants targeting cancer and infectious diseases</article-title><source>Pharmaceutics</source><volume>13</volume><year>2021</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.3390/pharmaceutics13020142</pub-id><pub-id pub-id-type="pmcid">PMC7911620</pub-id><pub-id pub-id-type="pmid">33499143</pub-id></element-citation></ref><ref id="bib0565"><label>113</label><element-citation publication-type="journal" id="sbref0565"><person-group person-group-type="author"><name name-style="western"><surname>Kasturi</surname><given-names>S.P.</given-names></name><name name-style="western"><surname>Rasheed</surname><given-names>M.A.U.</given-names></name><name name-style="western"><surname>Havenar-Daughton</surname><given-names>C.</given-names></name><name name-style="western"><surname>Pham</surname><given-names>M.</given-names></name><name name-style="western"><surname>Legere</surname><given-names>T.</given-names></name><name name-style="western"><surname>Sher</surname><given-names>Z.J.</given-names></name><name name-style="western"><surname>Kovalenkov</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Gumber</surname><given-names>S.</given-names></name><name name-style="western"><surname>Huang</surname><given-names>J.Y.</given-names></name><name name-style="western"><surname>Gottardo</surname><given-names>R.</given-names></name><etal/></person-group><article-title>3M-052, a synthetic TLR-7/8 agonist, induces durable HIV-1 envelope-specific plasma cells and humoral immunity in nonhuman primates</article-title><source>Sci Immunol</source><volume>5</volume><year>2020</year><pub-id pub-id-type="doi" assigning-authority="pmc">10.1126/sciimmunol.abb1025</pub-id><pub-id pub-id-type="pmcid">PMC8109745</pub-id><pub-id pub-id-type="pmid">32561559</pub-id></element-citation></ref><ref id="bib0570"><label>114</label><element-citation publication-type="journal" id="sbref0570"><person-group person-group-type="author"><name name-style="western"><surname>Kuai</surname><given-names>R.</given-names></name><name name-style="western"><surname>Sun</surname><given-names>X.</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>W.</given-names></name><name name-style="western"><surname>Ochyl</surname><given-names>L.J.</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Y.</given-names></name><name name-style="western"><surname>Hassani Najafabadi</surname><given-names>A.</given-names></name><name name-style="western"><surname>Scheetz</surname><given-names>L.</given-names></name><name name-style="western"><surname>Yu</surname><given-names>M.Z.</given-names></name><name name-style="western"><surname>Balwani</surname><given-names>I.</given-names></name><name name-style="western"><surname>Schwendeman</surname><given-names>A.</given-names></name><etal/></person-group><article-title>Dual TLR agonist nanodiscs as a strong adjuvant system for vaccines and immunotherapy</article-title><source>J Control Release</source><volume>282</volume><year>2018</year><fpage>131</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">29702142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2018.04.041</pub-id><pub-id pub-id-type="pmcid">PMC6056764</pub-id></element-citation></ref><ref id="bib0575"><label>115</label><element-citation publication-type="journal" id="sbref0575"><person-group person-group-type="author"><name name-style="western"><surname>Luo</surname><given-names>J.</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X.P.</given-names></name><name name-style="western"><surname>Xiong</surname><given-names>F.F.</given-names></name><name name-style="western"><surname>Gao</surname><given-names>F.X.</given-names></name><name name-style="western"><surname>Yi</surname><given-names>Y.L.</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z.</given-names></name><name name-style="western"><surname>Tan</surname><given-names>W.S.</given-names></name></person-group><article-title>Enhancing immune response and heterosubtypic protection ability of inactivated H7N9 vaccine by using STING agonist as a mucosal adjuvant</article-title><source>Front Immunol</source><volume>10</volume><year>2019</year><object-id pub-id-type="publisher-id">2274</object-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.3389/fimmu.2019.02274</pub-id><pub-id pub-id-type="pmcid">PMC6777483</pub-id><pub-id pub-id-type="pmid">31611875</pub-id></element-citation></ref><ref id="bib0580"><label>116</label><element-citation publication-type="journal" id="sbref0580"><person-group person-group-type="author"><name name-style="western"><surname>Junkins</surname><given-names>R.D.</given-names></name><name name-style="western"><surname>Gallovic</surname><given-names>M.D.</given-names></name><name name-style="western"><surname>Johnson</surname><given-names>B.M.</given-names></name><name name-style="western"><surname>Collier</surname><given-names>M.A.</given-names></name><name name-style="western"><surname>Watkins-Schulz</surname><given-names>R.</given-names></name><name name-style="western"><surname>Cheng</surname><given-names>N.</given-names></name><name name-style="western"><surname>David</surname><given-names>C.N.</given-names></name><name name-style="western"><surname>McGee</surname><given-names>C.E.</given-names></name><name name-style="western"><surname>Sempowski</surname><given-names>G.D.</given-names></name><name name-style="western"><surname>Shterev</surname><given-names>I.</given-names></name><etal/></person-group><article-title>A robust microparticle platform for a STING-targeted adjuvant that enhances both humoral and cellular immunity during vaccination</article-title><source>J Control Release</source><volume>270</volume><year>2018</year><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">29170142</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1016/j.jconrel.2017.11.030</pub-id><pub-id pub-id-type="pmcid">PMC5808851</pub-id></element-citation></ref><ref id="bib0585"><label>117</label><element-citation publication-type="journal" id="sbref0585"><person-group person-group-type="author"><name name-style="western"><surname>Hanson</surname><given-names>M.C.</given-names></name><name name-style="western"><surname>Crespo</surname><given-names>M.P.</given-names></name><name name-style="western"><surname>Abraham</surname><given-names>W.</given-names></name><name name-style="western"><surname>Moynihan</surname><given-names>K.D.</given-names></name><name name-style="western"><surname>Szeto</surname><given-names>G.L.</given-names></name><name name-style="western"><surname>Chen</surname><given-names>S.H.</given-names></name><name name-style="western"><surname>Melo</surname><given-names>M.B.</given-names></name><name name-style="western"><surname>Mueller</surname><given-names>S.</given-names></name><name name-style="western"><surname>Irvine</surname><given-names>D.J.</given-names></name></person-group><article-title>Nanoparticulate STING agonists are potent lymph node-targeted vaccine adjuvants</article-title><source>J Clin Invest</source><volume>125</volume><year>2015</year><fpage>2532</fpage><lpage>2546</lpage><pub-id pub-id-type="pmid">25938786</pub-id><pub-id pub-id-type="doi" assigning-authority="pmc">10.1172/JCI79915</pub-id><pub-id pub-id-type="pmcid">PMC4497758</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements</title><p id="par0220">We acknowledge Vinicius Suzart for helping to generate the visual model in <xref rid="fig0015" ref-type="fig">Figure 3</xref> created with <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://BioRender.com" id="intr0030">BioRender.com</ext-link>. We acknowledge Asad Abbas for helping proof the review.</p></ack></back></article></pmc-articleset>